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Staphylococcus aureus, particularly the epidemic methicillin-resistant S. aureus (MRSA) 
USA300 strain, is a major cause of severe necrotizing lung, skin and systemic infection. 
Although these infections are generally attributed to the pathogen’s multiple toxins, exactly how 
S. aureus cause disease is not clearly defined. In this research, we sought to establish the role of 
necroptosis, a programmed form of necrosis, in the pathophysiology of S. aureus pneumonia, 
skin infection and sepsis. S. aureus, mainly through its multiple toxins, induced 
RIPK1/RIPK3/MLKL-mediated necroptosis in multiple host cells including human cell lines, 
freshly obtained alveolar macrophages, peripheral blood macrophages and epithelial cells. S. 
aureus toxin-associated pore-formation was essential for necroptosis, as cell death was blocked 
by exogenous K+ or dextran as well as by MLKL inhibition. To understand the role of 
necroptosis in S. aureus pneumonia, we used Ripk3-/- mice and mice treated with necrostatin-1s 
(Nec-1s), a potent inhibitor of RIPK1. Inhibition of necroptosis in a mouse model of pneumonia 
led to significantly improved outcome from S. aureus infection marked by increased bacterial 
clearance, preserved lung architecture, decreased inflammatory markers in the airway and 
retention of an anti-inflammatory macrophage population.  
In contrast, inhibiting necroptosis in vivo during skin infection led to worse outcome as 
determined by bacterial clearance and lesion sizes, which occurred in spite of the presence of 
 
 
neutrophils, macrophages and γδ T cells. Nec-1s-treated mice and Mlkl-/- mice had significantly 
larger lesions, increased cytokine response and more S. aureus recovered from the infected areas 
compared to control groups. We observed a similar outcome in Casp1/4-/- mice, which have 
limited ability to process IL-1β. Unlike Mlkl-/- mice, Ripk3-/- mice had improved outcome with 
increased bacterial clearance and decreased inflammation because of the effects of RIPK3 in 
activating the NLRP3 inflammasome and apoptosis during S. aureus skin infection. Casp1/4-/- 
immune cells showed a significant defect in their ability to kill S. aureus, whereas Mlkl-/- 
peritoneal exudate cells and bone marrow-derived macrophages did not. These results show that 
caspase-1 is essential for bacterial killing whereas necroptosis is necessary for regulating 
excessive inflammation. 
Similar to our findings in skin infection, inhibition of the executioner of necroptosis 
(using Mlkl-/- mice) or pyroptosis (using Casp1/4-/- mice) decreased survival in a mouse model of 
S. aureus sepsis. Ripk3-/- and wild type mice were equally resistant to S. aureus sepsis. Overall, 
these findings provide new insights into the complex roles of necrosome components in different 
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Chapter 1: Introduction 
 
Background on Staphylococcus aureus 
Staphylococcus aureus is a formidable bacteria capable of causing widespread types of infections 
ranging from skin and soft tissue disease to severe invasive infections with significant morbidity 
and mortality (1-5). Even though there are effective antibiotics to combat this pathogen, there is 
a growing resistance to current antibiotics. This medical concern along with the ability of S. 
aureus to infect healthy individuals and exacerbate comorbidity in various patients, begs for 
better understanding of this pathogen’s host interaction with the aim of coming up with improved 
therapies. 
The success of S. aureus lies in its ability to persist within its host and produce multiple 
virulence factors including adhesins, coagulases and toxins. S. aureus toxins target diverse types 
of host cells, contributing to immune evasion and promoting infection. These toxins fall into 
three categories: pore-forming toxins, “receptor interfering but not plasma membrane-damaging 
toxins,” and “secreted enzymes” that interfere with host defense mechanisms (6). S. aureus 
produces two forms of pore forming toxins, namely α-hemolysin (also known as Hla or α-toxin) 
and bi-component cytotoxins such as Leukocidin AB/GH (LukAB/LukGH), LukSF (also known 
as  Panton-Valentine Leukocidin, PVL), LukED and γ-hemolysin (HlgAB/LukAC) (7). At high 
concentrations, these toxins form pores on the host cell leading to loss of ions. At low 
concentrations, they interact with their receptors and stimulate a molecular signaling cascade 





as LukAB and PVL are specifically adapted to lyse human cells, while others like Hla can target 
a wide range of cells in multiple species.  
Hla is an important S. aureus toxin that has been shown to exacerbate several infections 
including lung, bone, systemic and skin infection (9). Upon binding to its receptor ADAM10, 
Hla forms an heptameric pore leading to loss of monovalent ions (such as K+) and loss of ATP 
from the host cell (10). Deletion of Hla or sequestration of Hla using antibodies significantly 
improve outcome during S. aureus skin and lung infections (11). Hla activates cellular signaling 
leading to cell death and production of pro-inflammatory cytokines such as IL-1β, IL-8 and IL-6 
(12-14). Thus, Hla is a critical toxin not only because it can lyse multiple host cells including 
immune, endothelial and epithelial cells but also because of its ability to induce a diverse pro-
inflammatory signaling in a host. 
 
Mouse models 
Most of the current understanding on the pathogenesis of S. aureus infections is derived 
from studies done using mouse models. These models have been invaluable, but they have 
significant limitations. First, S. aureus is better adapted to infect humans than mice. This 
pathogen produces many toxins that have higher tropism to human cells than to mouse cells. 
Panton-Valentine Leukocidin (PVL, which targets C5aR and C5L2 receptors) (15); Leukocidin 
A/B (LukAB, which targets the CD11b subunit of Mac-1 integrin) (16); γ-
hemolysin AB (HlgAB, which targets the chemokine receptors CXCR1, CXCR2 and CCR2), 
HlgCB (which targets the complement receptors C5aR and C5L2) (17) show higher binding 





Second, in several S. aureus mouse models, supra-physiological inoculum has to be used 
to establish infection. For example, in our mouse models of pneumonia, we use approximately 
107 CFU/mouse. However, humans are highly susceptible to S. aureus pneumonia even at doses 
that would not cause any serious infection in mice, especially during influenza pandemics.  
Third, many vaccines developed in mouse models have failed to translate their efficacy to 
humans (18). The failure is potentially because humans have completely different immune 
system from mice and mice poorly recapitulate human inflammatory responses (19, 20) and that 
S. aureus produces numerous human-specific toxins that limited vaccine studies in mice (7).  
These limitations can potentially be mitigated in two ways. The first way is to use 
primary human cells or human tissues grafted on mice. Human skin grafted on scid mice has 
already proved useful in studies of S. aureus skin infection (8). The second way, and which has 
more potential applications, is the use of “humanized” mouse models (21). “Humanized” mice 
have proven important in studying pathogens with human tropism such as HIV and Salmonella 
enterica serovar (22, 23). In a peritonitis model and skin model of S. aureus infection, 
humanized mice models illuminated our understanding of the human specific S. aureus pathogen 
PVL (24, 25). In our studies here, we use combinations of primary human cells and human skin 
grafts on mice. Future projects may use humanized mouse models. 
 
Host cells 
Epithelial cells are the first line of defense during S. aureus infection. Keratinocytes and lung 
epithelial cells, for example, provide a barrier to prevent S. aureus from invading deeper tissues 
and causing systemic infection. They secrete antimicrobial peptides such as cathelicidin and 





(26, 27). Epithelial cells recognize foreign substances such as pathogen-associated molecular 
patterns (PAMPs), which are associated with microbial organisms, and danger-associated 
molecular pattern (DAMPs), which are associated with cell damage or death, through Toll-like 
receptors (TLRs) and Nod-like receptors (NLRs). Activation of these receptors leads to 
production of key cytokines such as IL-1β, KC and MIP-1β to recruit immune cells (specifically 
neutrophils and macrophages) to clear the invading microorganisms.  
 
Neutrophils 
Neutrophils play a critical role in immune defense. During S. aureus pneumonia for example, 
lack of neutrophils contributes to poor bacterial clearance and worse outcome (28). IL-1- and IL-
17-mediated immune signaling are essential for recruitment of neutrophils and formation of 
neutrophil abscess and eventual clearance of pathogens in a mouse model of subcutaneous 
infection (26). Mice that cannot produce active IL-1β (Il1b-/-) or that cannot respond to this 
cytokine (Il1r-/-) develop bigger lesions and have poor bacterial clearance in S. aureus model of 
skin infection (26). A defect in the machinery that produces IL-1β (for example, a lack of 
Myd88, a key adaptor to TLR signaling; or inhibition of ASC-Caspase-1 pathway, which is 
essential for the processing of pro-IL1β to active form) leads to an impaired response to S. 
aureus in the skin. Thus, the recruitment of neutrophils to clear pathogens is essential for 
survival. 
 Once recruited to the site of infection, neutrophils immobilize and ingest 
microorganisms. They release neutrophil extracellular traps (NETs), a composition of chromatin 
and serine proteases, to arrest particles and invading organism so they can be phagocytosed by 





have evolved ways to evade them. S. aureus, for example, produces nuclease and adenosine 
synthase that converts NETs to deoxyadenosine, a product that is cytotoxic to immune cells (30). 
Other than NETs, neutrophils have other defense mechanisms including “respiratory busts” and 
degranulation. Respiratory busts is mediated by NADPH oxidases that produce superoxide, 
reactive oxygen species (ROS), which can then be converted to hydrogen peroxide and 
hypochlorous acid to kill ingested organisms. This NADPH pathway is so critical to immune 
defense that any defect in the pathway, for example in patients with chronic granulomatous 
disease (CGD), predisposes one to chronic infections (31). Aside from producing ROS, 
neutrophils can also undergo a process called degranulation that leads to the release of 
antimicrobial peptides such as lactoferrin and defensins and other enzymes such as gelatinases, 
elastases, collagenases, lysozymes and cathepsins (32). Thus, neutrophils are an essential part of 
immune defense against invading microorganisms.  
Although a neutrophil response is essential for bacterial clearance, an excessive 
recruitment of neutrophils can be counterproductive. Neutrophil enzymes such as gelatinases, 
elastases, collagenases and lysozymes can destroy local tissues. This destruction is particularly 
problematic in the lung, where extensive damage can lead to serious edema. Even in skin, 
excessive neutrophil-mediated inflammation can cause damage and impair bacterial clearance. 
This point can be best illustrated by two examples. First, treatment of MRSA with β-lactams 
causes poor crosslinking of peptidoglycan that leads to a robust activation of the inflammasome, 
an excessive neutrophil response and a subsequent worse outcome in skin infection (33). Second, 
CXC chemokines, which recruit immune cells including neutrophils and CD4+ T cells,  mediate 





findings show that a balance between optimal neutrophil recruitment and regulation of 
inflammation is essential for bacterial clearance while minimizing immunopathology. 
 
Macrophages 
Macrophages have two critical functions. First, they participate in immunoregulation. Local 
tissue macrophages such as alveolar macrophages and kupffer cells produce chemokines that 
recruit other immune cells including neutrophils to clear foreign objects including pathogens. 
Macrophages limit the amount of tissue damage that dead cells can induce by clearing dead or 
dying cells through a process called efferocytosis (35). Once the source of insult has been 
removed and dead cells cleared, macrophages secrete cytokines to dampen inflammation, 
contributing to immune resolution and a return to tissue homeostasis. 
The second essential function of macrophages is bacterial clearance. Several groups 
including our laboratory have previously shown the role of macrophages during S. aureus 
pneumonia (28, 36). Depletion of macrophages using clodronate-loaded liposomes worsens 
outcome in S. aureus pneumonia. Like neutrophils, macrophages are efficient phagocytes and 
thus are essential for bacterial clearance. Alveolar macrophages are adept in taking up S. aureus 
and killing them through reactive oxygen species (ROS) production and acidification of 
phagosomes. In response to S. aureus, resident macrophages produce chemokines such as Cxcl1, 
Cxcl2, Ccl2, Ccl3 and Ccl4 to recruit other immune cells including neutrophils to the site of 
infection (37).  
S. aureus has evolved ways to eliminate macrophages as an immune evasion strategy. 
Using multiphoton intravital microscopy, Wenigner and colleagues have shown that S. aureus, 





attraction and transmigration. An hla null S. aureus strain was cleared better than wild type strain 
because hla was able to induce a robust chemokine release, which led to an influx of neutrophils 
and eventual clearance of the pathogen (37).   
 
Macrophages in inflammation 
Macrophages broadly fall in two categories – classically activated M1 macrophages and 
alternatively activated M2 macrophages (38, 39). M1 macrophages are inflammatory and 
phagocytic, whereas M2 macrophages have anti-inflammatory and wound healing capabilities. 
M1 macrophages express IFN-regulatory factor 5 (IRF5) and their surface markers include CD86 
and CD80 (39, 40). On the other hand, M2 macrophages express YM1 and FIZZ1 proteins with 
MARCO, CD200R and CD206 as their surface markers. M1 and M2 macrophages have different 
cytokine profiles, with M1 producing pro-inflammatory cytokines such as TNF and IL-6 whereas 
M2 produce anti-inflammatory ones such as IL-10 and TGF-beta.  
Importantly, however, these characteristics are not static since macrophages are plastic. 
Macrophages can adopt different states at different times and they can express both of the 
markers of M1-like and M2-like macrophages at the same time in response to the constantly 
changing needs of their microenvironment (39). This plasticity affords them the ability to induce 
inflammation in response to an insult and to resolve inflammation as the tissue returns to 
homeostasis in the local environment. 
 
Mechanisms of cell death 
In the lifespan of an organism, cells can die either accidentally or deliberately. Accidental death 





intracellular organelles. Deliberate death is physiologically regulated and is often less 
detrimental to an organism than accidental death (41). There are several types of physiologically 
regulated forms of cell death, but the most understood ones are apoptosis, pyroptosis and 
necroptosis (Figure 1.1). The reason why cells evolved to die through multiple programmed 
ways is not fully known. Some of these forms of death serve redundant roles, but each has some 
unique functions. Whereas apoptosis is the only type of death that is known so far to be essential 
for natural development, three types of death participate in response to pathogens. However, they 
can have similar, unique or even opposing roles during infection. What is clear though is that an 
excessive or insufficient amount of any of these forms of death is detrimental to an organism, 
and thus the cell has to regulate them carefully. 
 
Apoptosis 
Apoptosis is a well-studied programmed mechanism of cell death. It is an essential part of 
development and tissue homeostasis (by eliminating unwanted cells) and part of immune defense 
(by removing infected cells). It is activated either through an extrinsic or intrinsic pathway (42) 
(Figure 1.1). The extrinsic pathway involves the stimulation of a death receptor (most of which 
belong to the TNF superfamily) including FasR and TNFR1. These receptors recruit cysteine-
dependent aspartate-directed protease (caspase)-8, which then processes the executioners of 
apoptosis, caspase-3 and 7. The intrinsic pathway, on the other hand, involves the release of 
cytochrome c from the mitochondria leading to the formation of Apaf-1 complex that activates 
caspase-9, which in turn activates the executioner caspase-3. Apoptosis is generally accepted to 





excessive or defective cells such as during thymocyte selection) and it involves generation of 
apoptotic cells that (before they release intracellular products) can be rapidly cleared by 
phagocytes. However, apoptosis, as a response to inflammatory stimuli or external assault (such 
as a response to cancer therapy or infection), is immunogenic (43).   
 When normal cells detach and lose contact from their epithelial cells and extracellular 
matrix (ECM), they lose critical survival signals from their “home” tissues and therefore undergo 
anoikis, a programmed form of cell death (44). Anoikis is a special type of apoptosis that 
happens to cells that have lost contact with their ECM. It is mediated by caspase-3 and other 
signaling complexes associated with apoptosis. Little is known about the role of anoikis in 
infections. Its role in tumorigenesis is well appreciated, as cancer cells evolve different strategies 
to subvert anoikis enabling them to metastasize (45).  
 
Pyroptosis 
Pyroptosis is a caspase-dependent form of cell death that is mediated by caspase-1 (Figure 1.1). 
Caspase-11 in mice (or its human equivalent, caspase-4) can also trigger pyroptosis (46). Other 
caspases that may participate in pyroptosis, but that are less well understood, are caspase-5 and -
12. Caspase-1 is processed in a supramolecular complex called the inflammasome, which senses 
a wide variety of agonists through their Nod-like receptors (NLRs). The NLRP3 is activated by 
several compounds including crystals, pore-forming toxins, reactive oxygen species, K+ efflux, 
extracellular ATP; NLRC4 is activated by flagellin; and NLRP1 is activated by anthrax lethal 
toxin. Another inflammasome complex is AIM2, which detects dsDNA (46). These 





fragment). It was recently shown that caspase-1 cleaves gasdemin D, which executes pyroptotic 
cell death (47).  
Pyroptosis and inflammasome activation play an important role in inflammation. 
Pryoptosis leads to loss of plasma membrane and a release of inflammatory products such as 
HMGB1 and IL-1α (48). Aside from cell death, the inflammasome processes two important 
inflammatory cytokines, pro-IL-1β and pro-IL-18. These cytokines have several roles including 
attracting immune cells such as neutrophils and macrophages, inducing production of other 
inflammatory cytokines such as TNF and IL-6, and contributing to wound healing (48). 
Apoptosis and pyroptosis are well studied in the context of S. aureus infection. Apoptosis 
has been shown to participate S. aureus clearance (49). Pyroptosis, which can be mediated by S. 
aureus pore forming toxins such as Hla and PVL, has a complex role – it exacerbates 








Figure 1.1: Major cell death pathways  
(A) Apoptosis is activated either through an extrinsic or intrinsic pathway. The extrinsic pathway requires 
caspase-8 and the intrinsic one requires caspase-9. Caspase-8 and -9 activate executioner caspases that 
mediate cell death. Apoptosis is less inflammatory since it generates apoptotic cells that can be rapidly 
cleared by phagocytes. 
(B) Necroptosis is activated by RIPK1 and RIPK3 and is executed by mixed lineage kinase domain-like 
(MLKL) protein.  
(C) Pyroptosis is mediated by caspase-1/11/4/5, which process the inflammatory cytokines IL-1β and IL-
18. 
This image is being used under a License Agreement between Kipyegon Kitur and The American 
Association for the Advancement of Science provided by Copyright Clearance Center (license # 
3846690689031) (52).  
 
Necroptosis 
Necroptosis is a caspase-independent programmed form of cell death that requires receptor-





kinase domain-like (MLKL) protein (43, 53) (Figure 1.1). Necroptosis can be triggered by 
stimulation of several receptors such as the death receptors (TNFR, TRAIL and FAS), Toll-like 
receptors (specifically TLR3 and TLR4), or the T cell receptor (TCR) in the absence of active 
caspase-8 (Figure 1.2). Necroptosis is well studied in the context of the pleotropic cytokine 
TNF. Activation of TNF receptor (TNFR1) leads to the recruitment of RIPK1 through its death 
domain (DD). RIPK1 can then recruit RIPK3 through RIP homotypic interaction motifs (RHIM) 
(54). Other receptors that have RHIM and can recruit RIPK1 are TLR3, TLR4 and IFNAR. DNA 
and type 1 interferon (IFNs) can also activate necroptosis through DAI and IFNAR1 respectively 
(55) (Figure 1.2). When caspase-8 is blocked (such as in the presence of pan-caspase inhibitor, 
Z-VAD), RIPK1 recruits RIPK3 via RHIM, and the two kinases auto-phosphorylate. Activated 
RIPK3 then phosphorylates its substrate, the pseudokinase MLKL, leading to necroptosis.   
Exactly how MLKL executes cell death is unresolved. Phosphorylated MLKL 
translocates to the plasma membrane and oligomerizes to form a pore leading to a loss of 
essential ions in the cell, and eventually cell death.(56) The exact ions that contribute to 
necroptosis are controversial, with some groups suggesting Ca2+, others proposing Na+, and 







Figure 1.2: Necroptosis is activated by a diverse upstream signaling  
(A) TNFR stimulation can lead to several signaling cascades. Complex I (which is composed of TRADD, 
RIPK1, TRAF2, IAP1, IAP2 and LUBAC) activates AP-1 and NF-kB, leading to production of inflammatory 
cytokines and promotion of cell survival. Complex IIa (composed of TRADD, FADD and caspase-8) is the 
canonical extrinsic apoptosis pathway; it is activated when complex I is destabilized for example by a 
cytotoxic agent such as cycloheximide. Complex IIb is also apoptosis, but differs from complex I by its 
dependence on RIPK1-RIPK3 scaffolding functions, which leads to activation of caspase-8. Necrosome 
complex (RIPK1-RIPK3-MLKL) triggers necroptosis in the absence of active caspase-8. Necroptosis 
requires both the scaffolding and kinase activities of RIPK1 and RIPK3, which phosphorylate MLKL to 
induce necroptosis.  
(B) FASL induces a similar signaling to TNF, except that it cannot activate NF-κB or AP-1 cascade.  
(C) TLR3 and TLR4-induced necroptosis is mediated by the RHIM-containing adapter TRIF, which 
recruits RIPK1 and RIPK3 complex.  
(D) Viral double-stranded DNA (vDNA) stimulates DNA-dependent activator of IFN regulatory factors 
(DAI), which recruits RIPK3 through its RHIM domain to induce RIPK1-independent necroptosis.  
(E) IFNAR1 induces transcriptional production of necrosome components that are assembled in the 
presence of TNR1 and TLR4 stimulus.  
This image is being used under a License Agreement between Kipyegon Kitur and Nature Publishing 






Mouse models have shed light into the complex functions of necroptosis-mediating 
proteins. For instance, Ripk1-/- mice die soon after birth, whereas Ripk3-/- and Mlkl-/- mice are 
viable and healthy (60). The function of RIPK1 in necroptosis is context dependent. RIPK1’s 
kinase function, which can be inhibited by necrostatin-1 and its analogs, triggers necroptosis. On 
the other hand, RIPK1’s scaffolding function inhibits necroptosis and regulates other cell 
survival activities including NF-κB activation (61).  
 
Necroptosis in response to microbial pathogens 
Similar to other forms of cell death such as apoptosis and pyroptosis, necroptosis is a critical part 
of cellular response to microbial pathogens. Several pathogens have evolved ways to modulate 
this pathway to their advantage (62). Necroptosis generally leads to a release of intracellular 
pathogens such as viruses and bacteria. This release can promote local inflammation, which 
helps clear the viruses. Excessive inflammation, however, can be damaging and needs to be 
regulated. 
Vaccinia virus (VV), murine cytomegalovirus (MCMV) and influenza A virus best 
exemplify the complex role of necroptosis during viral infection. VV, a large double-stranded 
DNA virus, produces B13R, a potent caspase inhibitor (63). Caspase-8 inhibition by B13R 
promotes activation of TNFR-mediated necroptosis and eventual clearance of VV by mouse 
fibroblasts (64). During VV infection, Ripk3-/- and Tnfr2-/- mice showed reduced necrotic 
damage, but impaired VV clearance and eventually succumbed to infection (65). Similarly, 
MCMV activates necroptosis through DNA-dependent activator of interferon regulatory factors 
(DAI/ZBP1), promoting clearance. However, this virus has evolved vIRA, a RHIM-containing 





during influenza A virus pneumonia, however, is detrimental not because it impairs viral 
clearance but because it perturbs pulmonary homeostasis and leads to damaging inflammation in 
the airways (67).  
As in viral infections, necroptosis as a response to bacterial infection plays diverse 
functions. Salmonella enterica serovar Typhimurium (S. Typhimurium) targets and kills 
macrophages through necroptosis, which is mediated by type 1 interferons. Ifnar-/- and Ripk3-/- 
mice have increased clearance and survival during S. Typhimurium infection (68). Necrosome 
components during Mycobacterium tuberculosis (MTB) play a complex role. ROS, which is 
upstream of cell death, helps with MTB clearance. However, if cell lysis is allowed to proceed, it 
leads to release and dissemination of MTB. Thus, inhibitors that target cyclophilin D or acid 
sphingomyelinase, which are downstream of ROS, but upstream of cell death protects from 
infection in a zebrafish model (69). Caspase-8 and RIPK3 mediate clearance of Yersinia pestis 
through their activation of the inflammasome. Deletions of both CASP8 and RIPK3 (but not 
RIPK3 alone) lead to reduced activation of caspase-1 and production of pro-inflammatory 
cytokines, which increases susceptibility to infection (70, 71). These examples illustrate the 
complex role of necroptosis in controlling or exacerbating infections. 
 
Necroptosis in host defense 
Necrosome components can drive inflammation through cell death or by activating the 
inflammasome. Necroptosis is seen as proinflammatory because it leads to the release of 
intracellular components such as HMGB1 and DNA, which are potent activators of 
inflammation. The indirect way in which the necrosome components can activate inflammation 





are data suggesting that these components can activate NLRP3 inflammasome. Depletion of 
IAPs in dendritic cells leads to activation of the NLRP3 inflammasome in a RIPK3-dependent 
manner (72). TLR signaling promotes inflammasome activation when caspase-8 and IAPs are 
blocked (73). In the context of disease, RNA viruses activate the inflammasome through RIPK1-
RIPK3-Drp1- NLRP3 pathway leading to viral clearance (74). RIPK3 leads to exuberant IL-1β 
production promoting injury in a dextran sodium sulfate (DSS) colitis model (75). Thus, the 
necrosome components and inflammation are intertwined and both are critical in the 
pathogenesis of many diseases. 
The consequences of necroptosis are not necessarily proinflammatory. Although 
necroptosis results in the release of inflammatory intracellular components, it may decrease 
inflammation by eliminating the cells that produce cytokines and inflammatory products (76, 
77). Additionally, cell death releases viable intracellular pathogens, which can then be 
effectively cleared by bactericidal neutrophils and thus removing the source of inflammatory 
stimuli (77). Therefore, the consequences of necroptosis are complex and likely dependent upon 
the nature of the pathogen and site of infection.    
 
Necroptosis in S. aureus infection 
Necroptosis plays a role in releasing intracellular pathogens including viruses and some bacteria 
such as S. Typhimurium. S. aureus is both an intracellular and extracellular organism that causes 
serious infections accompanied by cell death, inflammation and tissue necrosis. The mechanism 
by which S. aureus causes inflammation and tissue damage is not well understood. We wanted to 
define the consequences of necroptosis in S. aureus infection, specifically its role in bacterial 





cells or does it participate in clearance by releasing intracellular S. aureus so that they can be 
taken up by cells that are more bactericidal? Does necroptosis participate in immunoregulation 
by eliminating inflammatory cells or does it add to inflammation by releasing inflammatory 
products?  
In the following chapters, we address the complex roles of necroptosis in S. aureus 
infection in two parts. In the first section, we define the contribution of necroptosis in a mouse 
model of pneumonia. We show that S. aureus toxins induce lung damage through necroptosis. In 
the second section, we demonstrate the complex role of necroptosis in dampening inflammation 
and improving outcome during S. aureus skin and systemic infection. Ultimately, this research 

















Chapter 2: Staphylococcus aureus toxins induce lung damage through necroptosis 
 
Introduction 
Staphylococcus aureus is a major cause of pneumonia, particularly ventilator-associated and 
community-acquired pneumonia, and is a significant cause of morbidity and mortality during 
influenza epidemics (78-80). S. aureus pneumonia is often accompanied by excessive 
inflammation. During pneumonia, some level of inflammation – marked by the presence of 
neutrophils, monocytes, macrophages and inflammatory cytokines – is necessary for bacterial 
clearance. However, excessive inflammation in the lung, where clear airways are required for 
proper aeration, is damaging. Thus, a tight regulation of inflammation is essential. 
Alveolar macrophages, the most abundant immune cells in the normal airway, contribute 
to pathogen clearance and immune regulation (81). Aside from actively clearing foreign objects 
in the lung, alveolar macrophages produce inflammatory cytokines and antimicrobial peptides to 
kill pathogens. Macrophages are avid phagocytes, but S. aureus has evolved ways to evade them. 
S. aureus produces numerous virulence factors including pore-forming toxins that can lyse 
macrophages, thwarting their functions. The mechanism by which S. aureus kills macrophages 
and the implication of macrophage death in pneumonia are not fully understood.  
This chapter focuses on understanding S. aureus-macrophage interaction and the role of 
macrophages in regulating inflammation during pneumonia. We tested the hypothesis that S. 
aureus kills macrophages through necroptosis, contributing to lung damage. We show that S. 
aureus, mainly through its toxins, targets and kills macrophages through necroptosis leading to 





resulting in increased bacterial clearance, better resolution of inflammation and significantly 
improved outcome in a mouse model of S. aureus pneumonia.  
 
Results 
S. aureus induces necrosis in macrophages – USA300 S. aureus expresses multiple toxins that 
can induce leukocyte death through multiple mechanisms. To document the efficiency at which S. 
aureus kills macrophages, we measured cytotoxicity using lactate dehydrogenase (LDH) assay in 
THP-1 cells, a macrophage-like cell line, infected with wild type (WT) or hla null S. aureus 
strain. Although the rate of cytotoxicity over the first 2 hours was greatest in THP-1 cells exposed 
to WT as compared to those exposed to hla null strain, cytotoxicity was similar in cells infected 
with any of the USA300 strains by 3 hours (Figure 2.1A). These results show that macrophages 
are highly susceptible to S. aureus killing. 
We next wanted to understand the mechanism by which S. aureus was killing 
macrophages. To determine if macrophage death were mediated by caspases, we pretreated THP-
1 cells with the pan-caspase inhibitor, Z-VAD, and infected the cells with S. aureus for 2 hours. 
Z-VAD significantly decreased S. aureus-induced cytotoxicity in THP-1 cells (Figure 2.1B). 
THP-1 cells treated with Z-VAD released reduced amounts of IL-1β (Figure 2.1C), suggesting a 
possible contribution of pyroptosis to macrophage death. These results confirm previous findings 
that toxin production by S. aureus induces a caspase-mediated cell death, accompanied by the 
release of mature IL-1 in several model systems (12, 50). 
We measured the relative contribution of apoptosis – a programmed form of cell death 
that is executed by caspase 3/7 (42) – in the killing of THP-1 cells by S. aureus. Incubation of 





contrast to a staurosporine-treated control (Figure 2.1D). Although we observed S. aureus-
induced caspases 3/7 activation (Figure 2.1E), inhibition of these caspases did not prevent S. 
aureus-induced THP-1 cytotoxicity (Figure 2.1F). Thus, despite that S. aureus activates caspase 
3/7, apoptosis seems not to be the dominant pathway through which S. aureus kills immune cells. 
 
 
Figure 2.1: S. aureus induces necrosis in macrophages 
(A) Cytotoxicity in THP-1 cells treated with S. aureus USA300 (WT) or its α-hemolysin (hla) mutants at 
MOI of 10 for the duration indicated.  
(B) Cytotoxicity in THP-1 cells pretreated with 20 µM Z-VAD or DMSO for 1 hour and stimulated with S. 
aureus for 2 hours.  
(C) Secreted IL-1β levels as measured by ELISA in THP-1 cells from “B”. 
(D) Images of primary human macrophages stimulated with PBS, WT USA300 (SA) or staurosporine for 2 
hours (magnification x400). 
(E) Caspase 3/7 activation in THP-1 cells pretreated with 20 µM caspase 3/7 inhibitor or DMSO for 1 hour 
and stimulated with S. aureus for 2 hours.  
(F) Cytotoxicity in THP-1 cells from “E.”  
Data are represented as mean ± SD of three or more technical replicates and are a representative of two 
to four independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and NS stands for “not significant.” 
  
S. aureus kills macrophages through necroptosis – Necroptosis is a caspase-independent 





which disrupts the integrity of the plasma membrane when activated (53). To determine if S. 
aureus induces necroptosis, we infected THP-1 cells with USA300 and measured the level of 
phosphorylated MLKL (pMLKL). We observed pMLKL in THP-1 cells after 2 hours of infection 
(Figure 2.2A). We determined whether biochemical inhibitors of necroptosis – necrostatin-1, 
which targets (RIPK1); and necrosulfonamide (NSA), which inhibits MLKL – could rescue 
macrophages from death. A dose-dependent inhibition of S. aureus-induced THP-1 cytotoxicity in 
the presence of necrostatin-1 (Nec-1) was observed (Figure 2.2B). The MLKL inhibitor NSA, as 
well as necrostatin-1s (Nec-1s), a more stable and potent analog of Nec-1, also protected human 
THP-1 cells from death as well as human peripheral-derived macrophages (Figures 2.2C and 
2.2D). NSA also protected freshly harvested human alveolar macrophages from S. aureus induced 
cytotoxicity (Figure 2.2E). To confirm the results we obtained using biochemical inhibitors, we 
used genetic means to block necroptosis. We observed that gene silencing using siRNA targeting 
RIPK3 or MLKL in THP-1 cells decreased S. aureus-induced cytotoxicity (Figures 2.2F and 
2.2G). Ripk3-/- mouse alveolar macrophages showed decreased cytotoxicity compared to WT 







Figure 2.2. S. aureus induces necroptosis in macrophages  
(A) Western blot showing primary human macrophages that were stimulated for 2 hours with S. aureus 
(SA) or PBS and blotted with antibodies against phosphorylated MLKL (pMLKL), MLKL and actin.  
(B) Cytotoxicity in THP-1 cells pretreated with increasing concentrations of necrostatin-1 stable (Nec-1s) 
and incubated with S. aureus or PBS for 2 hours.  
(C) Cytotoxicity in THP-1 cells pretreated for 1 hour with 200 µM necrostatin-1 stable (Nec-1s), 10 µM 
necrosulfonamide (NSA) or DMSO and incubated with S. aureus or PBS for 2 hours determined by LDH 
assay.  
(D) Cytotoxicity in primary human macrophages pretreated with 10 µM NSA, 200 µM Nec-1s or DMSO. 
(E) Cytotoxicity in freshly obtained human alveolar macrophages pretreated with 10 µM NSA or DMSO).  
(F) THP-1 cells were transfected for 72 hours with RIPK3, MLKL small interfering RNA (siRNA) or siRNA 
scrambled control (siScr). mRNA and protein levels of RIPK3 and MLKL was measured by quantitative 
real time PCR and western blot. 
(G) Cytotoxicity in THP-1 cells with depleted RIPK3 or MLKL and infected with S. aureus for 2 hours.  
(H) Cytotoxicity in primary alveolar macrophages from WT and Ripk3-/- mice incubated with USA300 MOI 
of 100 for 2 hours.  
Data are a representative of two to four independent experiments. Data are represented as mean ± SD of 
three or more technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
S. aureus toxins contribute to macrophage necroptosis – We next hypothesized that S. aureus 
virulence factors, specifically pore-forming toxins, are the activators of necroptosis in 
macrophages. S. aureus produces multiple toxins that are adept in killing human and murine 
leukocytes. The agr locus is a global regulator of multiple S. aureus virulence factors including 
toxins such as Hla, PVL, LukAB, and PSMs. To test the hypothesis that S. aureus toxins 





lukSF (pvl) mutants and their supernatants. Live WT and pvl null mutants and their supernatants 
killed THP-1 cells effectively, whereas live mutants and supernatants from agr, hla, 
psm (psmα/β/hld), lukAB showed attenuated killing of THP-1 cells (Figures 2.3A and 2.3B). pvl 
and WT had the same level of killing despite a robust expression of pvl by the WT strain 
(Figures 2.3A, 2.3B and 2.3C). NSA effectively decreased the cytotoxicity induced by these S. 
aureus strains and their supernatants (Figures 2.3A and 2.3B). Thus, cytotoxicity was not 
dependent upon the expression of any one specific toxin since NSA protected cytotoxicity 
associated with WT and toxin-null USA300 strains 
Hla is one of the most important S. aureus toxins, which has been shown to lyse both 
epithelial and immune cells leading to necrotizing pneumonia. We showed that purified Hla 
killed THP-1 cells in a dose-dependent manner and NSA could significantly decrease the Hla-
induced cell death (Figure 2.3D). We sought to show that the effect that we observed was due to 
Hla-toxin activity and its ability to induce a signaling cascade (possibility through its interaction 
with its receptor, ADAM10). We stimulated cells with hla and hla complemented with Hla H35L 
plasmid (hlaH35L), which produces Hla that can interact with ADAM10 but that cannot 
assemble to form a pore on the host cell (14), a phla (an hla strain complemented with Hla-
producing plasmid) in the presence of NSA or DMSO. We observed that hla null and hlaH35L 
strains had limited killing ability compared with phla and WT strains (Figures 2.3E and 2.3F). 
NSA significantly decreased cytotoxicity induced by these strains (Figure 2.3F). Thus, S. aureus 







Figure 2.3. Necroptosis inhibitors can inhibit S. aureus toxin-induced cell death  
(A) Cytotoxicity in THP-1 cells pretreated with 10 µM NSA or DMSO and infected with agr, hla, psm 
(α/β/hld), lukAB, pvl and wild type (WT) USA300 S. aureus mutants for 2 hours (*p < 0.005).  
(B) Cytotoxicity in THP-1 cells pretreated with NSA or DMSO and exposed to supernatant harvested from 
mutants in “A.” (*p < 0.0001). 
(C) Western blot showing the expression of PVL in supernatants from pvl and WT USA300 strains. 
(D) Cytotoxicity in THP-1 cells pretreated with NSA or DMSO and exposed to purified Hla for 2 hours (*p < 
0.05). 
(E) Western blot showing the expression of Hla in supernatant harvested from hla mutant, hla mutant 
complemented with hlaH35L or hla plasmid and WT. 
(F) Cytotoxicity in THP-1 cells pretreated with NSA or DMSO and exposed to supernatant harvested from 
hla, hlaH35L, phla plasmid and WT (*p < 0.05). 
Data are a representative of two to four independent experiments. Data are represented as mean ± SD of 
three or more technical replicates. * p < 0.05 
 
The necrosome complex and the inflammasome share components – It has previously been 
shown that the necrosome components (particularly RIPK3) can influence the activation of the 
NLRP3 inflammasome (72). It is also known that S. aureus Hla can activate the NLRP3 
inflammasome through K+ efflux (82). We tested the hypothesis that the necrosome components 
modulate the inflammasome during S. aureus infection. To test this hypothesis, we infected THP-
1 cells with WT and hla null strains in the presence of a necroptosis inhibitor. We observed that 





and production of IL-1β (Figures 2.4A and 2.4B). NSA significantly inhibited inflammasome 
activation, almost to the extent induced by the hla null S. aureus strain (Figures 2.4A-C). Similar 
to NSA, extracellular K+ decreased cell death and IL-1β production further showing a link 
between necroptosis and the inflammasome (Figures 2.4D and 2.4E). However, production of 
ROS, which has previously been shown to mediate RIPK3’s activation of NLRP3 (74), was not 
involved since N-acetyl-cysteine (NAC) did not decrease IL-1β production or cell death (Figures 
2.4E and 2.4F). Dextran, an osmoprotectant, prevented THP-1 death and IL-1β release (Figures 
2.4G and 2.4H). Thus, the necrosome and the inflammasome components are intertwined and 








Figure 2.4. The necrosome and the inflammasome components are intertwined  
(A) Caspase-1 western blot of THP-1 cells pretreated with NSA or DMSO and exposed to SA supernatant 
for 2 hours.  
(B) Levels of IL-1β as quantified by ELISA in THP-1 cells pretreated with NSA or DMSO and exposed to 
SA supernatant for 2 hours (*p < 0.05).  
(C) Levels of IL-1β as quantified by ELISA in THP-1 cells pretreated with NSA or DMSO and exposed to 
increasing concentrations of purified Hla for 2 hours (*p < 0.05).  
(D) Cytotoxicity as measured by PI staining in THP-1 cells pretreated with 1 mM N-acetylcysteine (NAC), 
10 µM NSA, 60 mM KCl or PBS and exposed to SA supernatant for 2 hours (*p < 0.005).  
(E) IL-1β in samples in “D”. 
(F) ROS levels in samples in “D”.  
(G) Cytotoxicity as measured by LDH assay in THP-1 cells pretreated with 1 mM, 2.5 mM dextran or PBS 
and exposed to SA supernatant for 2 hours.  
(H) IL-1β in samples in “G”.  
Data are a representative of two independent experiments with three technical replicates (mean and SD). * 
p < 0.05, ** p < 0.01, *** p < 0.001. 
 
Pharmacological inhibition of necroptosis improves outcome in S. aureus pneumonia – After 
documenting that S. aureus kills macrophages through necroptosis, we hypothesized that the loss 
of this critical immune cell population contributes to poor bacterial clearance and damaging 
inflammation typical of S. aureus pneumonia. To test this hypothesis, we characterized the effects 
of a pharmacological inhibition of necroptosis on bacterial clearance and immune cell recruitment 
in a mouse model of S. aureus pneumonia. Necrostatin-1s-treated mice had significantly 
improved clearance of bacteria from airway fluid (Figure 2.5A). Macrophage numbers in the lung 
were slightly increased and neutrophil numbers were significantly increased in both airway 
(BAL) and lung of Nec-1s-treated mice compared to DMSO-treated group (Figures 2.5B and 
2.5C). Other immune cells such as CD4+ T cells and NK cells were increased after infection, but 
were not affected by Nec-1s-treatment at the baseline and after infection (Figures 2.5D and 
2.5E). Nec-1s-treatment resulted in decreased Kc, Il6 and Tnf as compared to the control group in 
the mRNA but not in the protein level (Figure 2.5F and 2.5G). Thus, even though Nec-1s has a 








Figure 2.5. Pharmacological blockade of necroptosis improves outcome in S. aureus pneumonia 
(A) C57BL/6J mice were treated with necrostatin-1 stable (Nec-1s) or DMSO and infected with USA300 
(SA). S. aureus colony forming units (CFU) recovered from BAL and lung were quantified and normalized 
to DMSO controls (ctrl).  
(B and C) Macrophages (Macs) in BAL and lung and neutrophils (PMNs) in BAL.  
(D) CD4+ T cells (CD4s) in lung. 
(E) Natural killer cells (NKs) in BAL and lung.  
(F) Cxcl1/Kc, Il6 and Tnf expression in the lung homogenate quantified by real time PCR compared to 
control (ctrl).  
(G) CXCL/KC, IL-6, TNF and IL-1β levels in the BAL of Nec-1s-treated mice after S. aureus infection.  
(H) FACS blots showing gating strategies for immune cells.  
Data are pooled from two independent experiments. Each point represents a mouse. Lines show median 
values. * p < 0.05, ** p < 0.01, *** p < 0.001 
 
Genetic inhibition of necroptosis improves outcome in S. aureus pneumonia – To confirm the 
results that we obtained with the pharmacological inhibitor of necroptosis, we used Ripk3-/- (also 





S. aureus infection. We compared the ability of WT C57BL/6J and Ripk3-/- mice to clear S. 
aureus infection (Figure 2.6). One day after infection, Ripk3-/- mice exhibited significantly 
increased S. aureus clearance from both the bronchial alveolar lavage fluid and lung as compared 
to WT mice (Figure 2.6A). The improved staphylococcal clearance correlated with better 
epithelial barrier function, as assessed by protein leakage into the BAL fluid and better 
preservation of normal lung architecture (Figures 2.6B and 2.6C). We also observed significant 
decreases in several proinflammatory cytokines/chemokines including IL-6, CXCL1/KC, IL-1β 
and IL-1α (Figures 2.6D and 2.6E). Together, these results show that necroptosis mediates 
damage during S. aureus pneumonia. 
 
 
Figure 2.6. Ripk3-/- mice have increased S. aureus clearance 
(A) CFU recovered in BAL and lung of Ripk3-/- or WT mice infected with USA300 (SA) for 18 hours. 
(B) Protein in the BAL fluid of WT and Ripk3-/- mice.  
(C) Hematoxylin and eosin stain (H&E) staining of WT and Ripk3-/- mice lungs (magnification of 100x; 





(D) Cxcl1/Kc, Il6 and Tnf levels in lung as measured by quantitative RT-PCR 
(E) CXCL1/KC, IL-6, TNF, IL-1β and IL-1α levels in the BAL fluid as measured by ELISA. 
Data are pooled from three independent experiments. Each point represents a mouse. Lines show median 
values. 
 
To determine the mechanism by which S. aureus mediated necroptosis, we infected WT 
and Ripk3-/- mice with WT and agr null USA300 strains. WT mice cleared both strains poorly in 
both BAL and lung as compared to Ripk3-/- mice (Figures 2.7A and 2.7B). WT mice exhibited 
increased clearance of agr null strain and preserved lung architecture after agr infection compared 
to after WT USA300 infection, whereas Ripk3-/- mice did not show any phenotype in the lung 
(Figures 2.7A and 2.7B). These results show that agr-regulated toxins activate necroptosis 
leading to impaired bacterial clearance.  
 
 
Figure 2.7. S. aureus toxins induce necroptosis leading to poor outcome during pneumonia 
(A) CFU recovered in BAL and lung of Ripk3-/- or WT mice infected with WT USA300 or agr strain. 
(B) Hematoxylin and eosin stain (H&E) staining of WT and Ripk3-/- mice lungs (magnification of 100x; 
insert, magnification of 400x) infected with WT USA300 or agr strain. 







S. aureus-induced necroptosis targets macrophages in a mouse model of pneumonia – We 
next hypothesized that S. aureus targets resident macrophages through necroptosis and these cells 
may not be easily replenished from the bone marrow or local stores. To test this hypothesis, we 
quantified the different types of immune cells recruited into the BAL and lung following S. 
aureus infection. PMNs were quickly recruited into the lungs within 4 h and they predominated 
the lung and BAL after 24 h of infection (Figures 2.8A and 2.8B). The predominance of alveolar 
macrophages in the airway in the uninfected mice was maintained at 4 hours post inoculation, but 
by 24 hours PMNs were the dominant immune cells in the infected lung (Figure 2.8C). NK cells, 
DCs and CD4+ T cells were readily detected after infection, with NK cells increasing in number 
in BAL after infection (Figures 2.8D-G). Considering that epithelial and immune cells produce 
neutrophil and macrophage chemokine production in response to infection, there was actually a 
net decrease in the absolute number of macrophages in the lung at 24 hours following infection 







Figure 2.8. Macrophage expansion is limited during S. aureus pneumonia 
(A) Number of neutrophils (PMNs) in BAL and lung of mice infected intranasally with S. aureus for 24 h.  
(C) Percentages of immune cell populations at 4 and 24 hours as compared to uninfected controls (UN) 
determined.  
(D and E) Natural killer cells (NKs) in BAL (D) and lung (E). 
(F) Dendritic cells (DCs) in BAL and lung.  
(G) CD4+ T cells in lung.  
(F) Macrophages (Macs) in BAL and lung.  
Data are pooled from three independent experiments. Each point represents a mouse. Lines show median 
values 
 
To confirm that the relative lack of alveolar macrophages was due to S. aureus-induced 
necroptosis, we measured the number of macrophages in Ripk3-/- mice after S. aureus pneumonia. 
Ripk3-/- mice had significantly more macrophages persisting in the BAL and lung after infection 
than WT mice (Figures 2.9A and 2.9B). No statistically significant differences in other immune 
cell populations including PMNs, DCs and NKs were observed (Figures 2.9C-F). We next 





recovered more dead macrophages in BAL of WT mice compared to Ripk3-/- mice (Figures 2.9G 
and 2.9H), confirming that the macrophages were dying through necroptosis. Thus, necroptosis is 




Figure 2.9. S. aureus-induced necroptosis targets macrophages in vivo 
(A) Number of macrophages (Macs) in Ripk3-/- and WT mice infected with S. aureus. 
(B) Neutrophils in BAL of Ripk3-/- and WT mice.  
(C) Macs in BAL and lung of Ripk3-/- and WT mice.  
(D) CD4+ T cells in lung of Ripk3-/- and WT mice.  
(E) Dendritic cells in BAL and lung of Ripk3-/- and WT mice.  
(F) NK+ T cells in BAL and lung of Ripk3-/- and WT mice.  
(G) Representative FACS blots of propidium iodide positive (PI+) macrophages in the BAL of WT and 
Ripk3-/- mice. 
(H) Quantification of PI+ macrophages in the BAL of WT and Ripk3-/- mice. 







Alveolar macrophages from Ripk3-/- have an anti-inflammatory phenotype in the setting of 
S. aureus pneumonia – We tested the hypothesis that the reason Ripk3-/- mice had improved 
bacterial clearance and decreased inflammation in the lung was that Ripk3-/- macrophages were 
more anti-inflammatory compared to WT macrophages. To test this hypothesis, we examined the 
abundance of specific markers on the pulmonary macrophages recovered from WT and Ripk3-/- 
mice (Figure 2.10). We first looked at the level of macrophage activation, which happens in the 
presence of pathogen, using CD54+ (ICAM+) marker. Compared with control mice, Ripk3-/- mice 
expressed more CD54+ macrophages in both BAL and lung (Figure 2.10A) showing their 
increased level of activation. CD86 expression, a pro-inflammatory macrophage marker, was not 
changed in WT and Ripk3-/- mice BAL and lung (Figure 2.10B), whereas the number of CD206, 
an anti-inflammatory marker was significantly increased in Ripk3-/- mice macrophages harvested 
from the lung (Figure 2.10C). Similarly, the other major anti-inflammatory receptor CD200R 
was significantly increased in the macrophage populations isolated from both BAL and lung 
(Figure 2.10D). The increase in anti-inflammatory macrophages corresponded to the decrease in 
proinflammatory cytokines (KC, IL-6, CXCL1/KC, IL-1β and IL-1α) noted in the Ripk3-/- mice 
(Figure 2.6D and 2.6E). Thus, Ripk3-/- mice, which are protected from macrophage loss through 
necroptosis, have increased number of macrophages with an anti-inflammatory phenotype and a 
corresponding decrease in production of major proinflammatory cytokines. These observations 
suggest that the critical function of alveolar macrophages in the setting of S. aureus infection is to 
regulate the inflammatory response, and that the loss of macrophages through necroptosis is a 







Figure 2.10. Pulmonary macrophages from Ripk3-/- mice have an anti-inflammatory phenotype  
(A) Absolute number of CD54+ macrophages (Macs) in BAL and lung of Ripk3-/- and WT mice. 
(B) CD86+ macrophages in BAL and lung. 
(C) CD206+ macrophages in BAL and lung. 
(D) CD200 receptor positive (CD200R+) macrophages in BAL and lung. 
(E) Gating strategies for macrophage markers.  
Data are pooled from two independent experiments. Each point represents a mouse. Lines show median 
values. 
 
Macrophage depletion leads to poor outcome during S. aureus pneumonia – To confirm 
further the contribution of macrophages, which are lost through necroptosis during S. aureus 
pneumonia, to the overall clearance of S. aureus from the lung, we treated mice with either PBS- 
or clodronate-loaded liposomes (Figure 2.11). Clodronate-loaded liposome depleted 95.4% and 
91.6% of macrophages in the BAL and lung respectively in uninfected group and the significant 





The consequences of macrophage depletion were evident in the significantly increased 
staphylococcal load recovered from both the BAL and lungs of the clodronate-treated mice 
(Figure 2.11B). We observed no significant difference in the number of neutrophils in either the 
airway or the lung (Figures 2.11C and 2.11D). However, macrophage-depleted mice had 
significantly greater ratio of staphylococci to neutrophil numbers at 24 hours post infection 
(Figure 2.11E). These results suggest that despite the presence of neutrophils, macrophages are 
essential for S. aureus clearance during pneumonia.   
 
 
Figure 2.11. Depletion of pulmonary macrophages impairs S. aureus clearance 
(A) Number of macrophages in BAL and lung of mice treated with clodronate- or PBS-loaded liposomes 
and infected intranasally with S. aureus. 
(B) CFU recovered from BAL and lung from macrophage depleted mice. 
(C, D) PMNs in BAL and lung 24 hours post-infection.  
(E) Ratios of CFU to PMNs in BAL and lung. 
Data are pooled from three independent experiments. Each point represents a mouse. Lines show median 
values. 
 
We next quantified the recruitment of other types of immune cells into the lungs and 





alveolar macrophages. We observed that clodronate-treatment led to a decrease in the number of 
DCs in the BAL at 4 hours post infection, but the number of DCs at 24 hours was significantly 
increased in the clodronate-treated group as well as in the lung (Figure 2.12A). The population of 
NK cells in the BAL by 4 hours post infection was not different but it was significantly increased 
in the lung at 4 hours in the clodronate-treated mice (Figure 2.12B). The number of NK cells 
changed after 24 hours, with more of them in BAL and no difference in lung in clodronate-treated 





Figure 2.12. Immune cells in macrophage-depleted mice 





(B) NKs in BAL and lung 4 h and 24 h post-infection.  
(C) CD4 T cells in lung 4 h and 24 h post-infection.  
(D) Representative FACS blots showing depleted Macs and unchanged PMNs after clodronate-treatment. 
Data are pooled from three independent experiments. Each point represents a mouse. Lines show median 
values.  
 
Macrophage-depleted mice had increased lung damage marked by worse histopathology 
and significantly increased loss of lung architecture after S. aureus infection (Fig 2.13A and 
2.13B). These results demonstrate that the regulatory functions of alveolar macrophages are 




Figure 2.13. Macrophages regulate inflammation in S. aureus pneumonia  
(A) Representative hematoxylin and eosin (H&E) stained imaged of mouse lung depleted of 
macrophages and infected with S. aureus (magnification 100x; insert, magnification 400x) 
(B) Protein in the BAL fluid in macrophage-depleted mice lung post S. aureus infection.  
Data are pooled from three independent experiments. Each point represents a mouse. Lines show median 
values.  
 
Compensation for macrophage depletion during S. aureus pneumonia – We wanted to 
understand if the reason the Ripk3-/- mice did well after S. aureus was solely due to macrophage 
necroptosis. Several mammalian cells can undergo necroptosis with the right stimulation, and 





(84). Using clodronate-loaded liposomes, we depleted macrophages in Ripk3-/- and WT mice and 
infected them with S. aureus for 24 hours (Figure 2.14A). As previously shown, depleting 
macrophages in WT mice worsens their outcome during S. aureus infection (Figure 2.14B and 
2.14C). However, depleting macrophages in Ripk3-/- mice did not affect outcome as they still had 
significantly improved S. aureus clearance as compared with WT mice and significantly 
decreased expression of proinflammatory cytokines (Figures 2.14B-D). These Ripk3-/- mice had 
significantly increased neutrophil numbers and a trending increase in the number of DCs, which 
likely contributed to their ability to clear infection (Figure 2.14E and 2.14F). The Ripk3-/- mice 
lacking macrophages have increased epithelial damage as evidenced by significantly increased 
levels of protein in BAL fluid, as compared with PBS controls (Figure 2.14G). Thus, even 
though S. aureus can target multiple cells and that other immune cells can compensate for the 
lack of macrophages, lung macrophages play a key role in regulating inflammation and their 






Figure 2.14. Depletion of pulmonary macrophages impairs S. aureus clearance 
(A) Number of macrophages in BAL and lung of Ripk3-/- and WT mice treated with clodronate- or PBS-
loaded liposomes and infected intranasally with S. aureus. 
(B and C) CFU recovered from BAL and lung from macrophage depleted Ripk3-/- and WT mice. 
(D) CXCL1/KC, IL-6, TNF and IL-1β levels in the BAL fluid of Ripk3-/- and WT mice. 
(E) Number of neutrophils in BAL and lung of Ripk3-/- and WT mice. 
(F) Number of DCs in BAL and lung of Ripk3-/- and WT mice. 
(G) Protein in the BAL fluid of WT and Ripk3-/- mice.  





In this chapter, we show that S. aureus-induced macrophage necroptosis contributes to a defect 
in bacterial clearance and resolution of inflammation. Inhibition of necroptosis using either Nec-





as did RIPK3 and MLKL knockdown by siRNA in vitro. NSA significantly reduced macrophage 
cytotoxicity induced by purified supernatant from WT S. aureus, suggesting that S. aureus toxins 
induce necroptosis.  
In a murine model of pneumonia, S. aureus toxin-induced necroptosis killed 
macrophages in the lung leading to acute inflammation. Nec-1s-treatment led to increased 
bacterial clearance. Compared to wild type C57BL/6 mice, Ripk3-/- mice had significantly 
improved outcome from S. aureus pneumonia. Pulmonary macrophages of Ripk3-/- mice were 
resistant to death and upregulated anti-inflammatory markers, CD200R and CD206. Improved 
macrophage survival in Ripk3-/- mice was associated with improved lung architecture and 
decreased inflammation as marked by protein leakage and inflammatory cytokines in the 
airways. Therefore, inhibition of necroptosis preserves macrophage population that helps clear 
pathogens and minimizes potentially damaging inflammation. 
We could not identify a single S. aureus pore-forming toxin that mediated necroptosis in 
vivo. In a mouse model of pneumonia, WT mice cleared the agr mutant better, but not to the 
same level as Ripk3-/- mice. Since agr is a “master” regulator of S. aureus virulence factors and 
yet agr-infected WT mice showed a dramatic clearance phenotype as Ripk3-/- mice, we did not 
expect a major phenotype with a single toxin. Understanding the “single” S. aureus toxin that 
“matters the most” in a mouse model of pneumonia is also difficult since some S. aureus toxins 
are human specific and others are differentially expressed in vivo. PVL, for example, is a human 
specific toxin and we did not expect to see a major effect with this toxin in mice (85-91).  
S. aureus can induce necroptosis in multiple host cells. It has been shown that S. aureus 
kills neutrophils through necroptosis (84) and we show in the next chapter the implications of S. 





WT mice, depleting macrophages in Ripk3-/- mice did not alter bacterial clearance phenotype in 
S. aureus pneumonia. This effect was possibly due to the compensation of macrophage roles by 
DCs and PMNs, which were increased in numbers in macrophage-depleted Ripk3-/- mice, 
potentially because these cells were also resistant to S. aureus-induced necroptosis. However, 
despite these compensatory effects, macrophage-depleted Ripk3-/- mice had poor preservation of 
lung architecture compared to Ripk3-/- mice with intact macrophages. Thus, even though 
macrophage bacterial clearance phenotype may be compensated by other immune cells, their 
anti-inflammatory phenotype may not be easily replaceable.  
In sum, this chapter has increased scientific understanding of the immunoregulatory role 
of macrophages. It also showed how S. aureus targets and kills this critical population leading to 
lung damage and demonstrated the therapeutic potential of specifically preserving macrophages 
and enhancing macrophage numbers during S. aureus pneumonia. Targeting the host response 
rather than developing new antimicrobial agents will potentially usher in a new and much needed 
generation of targeted therapies to protect critical immune cells from inflammatory death and 














Chapter 3: Necroptosis dampens inflammation leading to improved outcome during 
Staphylococcus aureus skin and systemic infection 
 
Introduction 
In the previous chapter, we showed that S. aureus kills macrophages, a cell population that is 
critical for bacterial clearance and regulation of inflammation, through necroptosis and thus 
leading to lung damage. In this chapter, we continue our quest to understand the role of 
necroptosis in the pathogenesis of two other common S. aureus diseases – skin and systemic 
infections. 
 
Necroptosis in Staphylococcus aureus skin infection 
Methicillin-resistant S. aureus strain (MRSA) USA300 is a leading cause of skin and soft 
tissue infection (92). It causes a wide-ranging form of skin infections extending from superficial 
infections to serious deep tissue infection. During S. aureus skin infection, a balance between a 
brisk inflammatory response to clear the pathogen and severe inflammation that may contribute 
to pathology is essential. Skin inflammation after S. aureus infection is often marked by the 
presence of abundant pro-inflammatory cytokines such as KC, IL-1β, TNF and IL-6 and an 
increase in the number of inflammatory cells such as neutrophils, monocytes, and macrophages. 
Abrogation of this inflammatory milieu, either by genetic mutation (such as using Myd88-/-, Il1r-
/-, Il1b-/- or Il17-/- mice) or by neutrophil depletion, leads to worse outcome during S. aureus 
infection  (26). On the other hand, excessive inflammation at the site of infection causes skin 





Keratinocytes can undergo apoptosis (as part of the natural differentiation process) or 
necroptosis (such as during infection or autoimmune disease), and the balance between the two is 
tightly regulated by RIPK3 and caspase-8 (61). As keratinocytes mature from the basal layer, 
which is made up of continuously dividing cells, to the corneal layer, which is made of 
corneocytes, they lose their organelles and die through a caspase-8-mediated non-inflammatory 
process (27). In the absence of caspase-8, necroptosis in the skin ensues (93). Similarly, deletion 
of Ripk1 in mice skin leads to a fulminant inflammation mediated by RIPK3-dependent 
necroptosis (61). Thus, necroptosis in skin can be inflammatory as it involves production of 
DAMPs such as DNA, HMGB1 and several cytokines including IL-1α and IL-33.  
Even though necroptosis leads to the release of inflammatory products, it also eliminates 
cells responsible for generating these products, an effect that may decrease inflammation over 
time. Necroptosis in cells suppresses excessive production of NF-kB-dependent inflammatory 
cytokines such as TNF and KC (76). Cell death also releases intracellular pathogens, which can 
then be phagocytosed and cleared by more competent immune cells such as neutrophils, 
eventually decreasing inflammation by removing the source of inflammatory stimuli (77). Thus, 
the role of cell death in regulating inflammation and the effects of inflammation during microbial 
infection is complex. Little is known about the role of necroptosis in S. aureus skin and systemic 
infection.  
Regulated inflammation accompanied by sufficient and efficient bacterial clearance 
determines outcome during S. aureus infection. We tested the hypothesis that necroptosis lessens 
inflammation and contributes to better outcome in S. aureus sepsis and skin infection. This 
chapter shows that inhibition of necroptosis leads to worse outcome as shown by decreased 





subcutaneous model of S. aureus infection. We confirmed these observations in a systemic 
model of S. aureus infection.  
 
Results 
S. aureus induces necroptosis in skin – To understand the importance of necroptosis during S. 
aureus skin infection, human skin grafted on SCID mice was infected with S. aureus for 3 days 
and the skin biopsies stained for phosphorylated MLKL (pMLKL), a marker of necroptosis. 
Confocal images of the grafts showed upregulation of MLKL and pMLKL in S. aureus infected 
skin (Figure 3.1A). pMLKL was present in most layers of the skin with strong prominence on 
the epidermis. S. aureus induced cytotoxicity in keratinocyte cell line (HaCaT) and primary skin 
cells (HEKn) and this form of cell death could be significantly decreased by RIPK1 inhibitor, 
Nec-1s; by RIPK3 inhibitor, GSK’872; and by MLKL inhibitor, NSA (Figures 3.1B-D). We 
observed a similar protection by NSA in primary keratinocytes (HEKn cells) (Figure 3.1E). 
Knockdown of MLKL by siRNA also decreased S. aureus induced death in HaCaT cells 







Figure 3.1. S. aureus induces necroptosis in skin cells 
(A) Representative images of sections obtained from S. aureus-infected human skin grafts on SCID mice 
and stained for DAPI (blue), pan cytokeratin (red) and MLKL or phospho-MLKL (Green). Magnification of 
200x.  
(B) Cytotoxicity in keratinocyte cell line (HaCaT) pretreated with 200 µM necrostatin-1 stable (Nec-1s) 
and infected with S. aureus MOI of 10 for 4 h.  
(C) Cytotoxicity in HaCaT cells pretreated with 10 µM GSK‘872.  
(D and E) Cytotoxicity in HaCaT cells (C) or primary keratinocytes (HEKn) (D) pretreated with 10 µM 
necrosulfonamide (NSA).   
(F) Cytotoxicity in HaCaT cells with MLKL knocked down with siRNA.  
(G) Western blot of HaCaT cells showing knockdown of MLKL by siRNA or scrambled control.  
Data are represented as bar graphs with mean ± SEM. *p<0.05, **p<0.01.  
 
 
Pharmacological inhibition of necroptosis leads to poor outcome in S. aureus skin infection 
– To understand the role of necroptosis during S. aureus skin infection, mice were infected 





DMSO control for 5 days. We observed that Nec-1s-treated mice had more CFU and bigger 
lesions compared to DMSO group (Figures 3.2A-C). Since immune cells, particularly 
neutrophils (PMNs), gamma-delta (γδ) T cells and macrophages (Macs), have been previously 
shown to be essential for S. aureus clearance, we looked at their numbers in Nec-1s and DMSO 
treated mice. Nec-1s treated mice had more PMNs, γδ T cells, and Macs (Figures 3.2D-F). The 
increased number of immune cells was accompanied by increased levels of inflammatory 
cytokines in Nec-1s treated mice (Figures 3.2G and 2H). The histopathology of Nec-1s-treated 
mice exhibited increased adiposity and necrosis and increased TUNEL staining after infection 
(Figures 3.2I and 3.2J). The poor outcome experienced by Nec-1s-treated mice occurred in 
spite of the presence of large number of immune cells suggesting that either immune cells 







Figure 3.2. Pharmacological inhibition of necroptosis leads to worse outcome in S. aureus skin 
infection  
(A) S. aureus CFU recovered on day 5 from mice were infected subcutaneously with S. aureus (SA) and 
treated with 10mg/kg necrostatin-1 stable (N) or DMSO control (D) for 5 days. 
(B) Representative images of mice showing lesions 5 days after infection.  
(C) Quantification of lesion sizes on day 5.  
(D-F) Number of neutrophils (PMNs) (D), gamma-delta (γδ) T cells (E), and macrophages (Macs) (F) on 
infected mice.  
(G) Cytokines from Nec-1s or DMSO treated mice and infected with PBS control. 
(H) Cytokines from Nec-1s or DMSO treated mice and infected with S. aureus. 
(I and J) Representative images of trichrome stain (I) or TUNEL stain (J) on skin biopsies of infected 
mice. Scale bars, 100 μm.  
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 
mean ± SEM. Results shown are pooled from at least two independent experiments. *p<0.05, **p<0.01.  
 
Necroptosis and pyroptosis are essential during S. aureus skin infection – To confirm the 
results we obtained by pharmacological inhibition of necroptosis, we subcutaneously infected 





days. Like Nec-1s-treated mice, Mlkl-/- mice had reduced bacteria clearance and displayed bigger 
lesion sizes than WT controls after S. aureus infection (Figures 3.3A-C). Trichrome and 
TUNEL staining also revealed extensive inflammation and damage in S. aureus infected Mlkl-/- 
and Casp1/4-/- mice with increased adiposity, TUNEL positive cells and overall inflammation in 
mutant mice (Figure 3.3D). Strikingly, Mlkl-/- mice had increased active caspase-1 (p20) at 
baseline and after infection (Figure 3.3E), potentially caspase-1 was compensating for the lack 
of Mlkl.  
We next wanted to determine the contribution of caspase-1 during S. aureus skin 
infection. Previous research has shown that IL-1β, which is processed by caspase-1, is essential 
for neutrophil recruitment and bacterial clearance in skin (26), but the exact role of pyroptosis 
during S. aureus skin infection has not been studied. To establish the role of pyroptosis during 
skin infection, we infected Casp1/4-/- mice with S. aureus for 5 days. On day 5, we obtained 
similar phenotypes in Casp1/4-/- mice to those in mice lacking Mlkl (Figures 3.3A-D). Together, 
these results show that the executioners of both necroptosis and pyroptosis participate in 








Figure 3.3. Mlkl-/- and Casp1/4-/- mice have worse outcome during S. aureus skin infection 
(A) S. aureus CFU recovered from Mlkl-/-, Casp1/4-/- and wild type (WT) mice infected subcutaneously 
with 2 x 106 CFU/mouse of S. aureus (SA) for 5 days  
(B) Representative images of lesions on infected mice.  
(C) Quantification of lesion sizes from (B).  
(D) Representative images of trichrome stain and TUNEL stain on skin biopsies of S. aureus-infected 
mice. Scale bars, 100 μm. 
(E) Immunoblot showing cleaved caspase-1 (p20), full-length caspase-1, actin and ponceau on skin 
homogenate of infected WT and Mlkl-/- mice.  
Each point represents a mouse and lines show median values. Results shown are pooled from at least 
two independent experiments. *p<0.05, **p<0.01.  
  
Necroptosis limits excessive inflammatory response in S. aureus skin infection – We tested 
the hypothesis that necroptosis reduces inflammation – marked by decreased cytokine production 
and recruitment of immune cells – and results in decreased damage during S. aureus skin 
infection. To test this hypothesis, we measured key inflammatory cytokines in Mlkl-/- mice after 
1 and 5 days of S. aureus infection. Compared to WT mice, Mlkl-/- and Casp1/4-/- mice showed 
no defect in killing S. aureus and recruiting immune cells including PMNs, gamma-delta T cells 
and macrophages after 1 day of infection (Figure 3.4A-C). At this earlier time point in infection, 





(CXCL10), MCP1 and MIG (CXCL9) (Figures 3.4D-F), cytokines that have previously been 
shown to mediate inflammatory damage in S. aureus skin infection. Most other cytokines 
including IL-1β and MCSF were trending lower (Figures 3.4D-F).  
 
 
Figure 3.4. Response of wild type, Mlkl-/- and Casp1/4-/- mice after 1 day of S. aureus skin infection  
(A) S. aureus CFU recovered from Mlkl-/-, Casp1/4-/- and wild type (WT) mice were infected 
subcutaneously with 2 x 106 CFU/mouse S. aureus USA300 (SA) for 1 day. 
(B and C) Numbers of neutrophils (PMNs), gamma-delta (γδ) T cells, and macrophages (Macs) in Mlkl-/- 
mice (B), Casp1/4-/- mice (C) and compared to WT mice.  
(D-F) Cytokines from WT and Mlkl-/- mice infected with S. aureus or PBS for 1 day.  
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 
mean ± SEM. Results shown are pooled from at least two independent experiments. *p<0.05.  
 
Five days after infection, Mlkl-/- and Casp1/4-/- had more immune cells (Figures 3.5A-C). 
Most of the important inflammatory cytokines including IL-1β, KC, MCSF, TNF, IL-1α, MCP1, 





3.5D and 3.5E). Casp1/4-/- mice did not show equally remarkable increase in inflammatory 
cytokines as Mlkl-/- mice did after infection (Figures 3.5F and 3.5G). These results suggest that 
the reason Mlkl-/- mice had poor outcome after S. aureus infection is not due to a defect in 
immune cell response, but rather due to excessive inflammation that impaired bacterial clearance 
and cause skin damage.  
 
 
Figure 3.5. Mlkl-/- mice have heightened inflammatory response to S. aureus skin infection 
(A-C) Number of neutrophils (PMNs) (A), gamma-delta (γδ) T cells (B), and macrophages (Macs) (C) in 
Mlkl-/-, Casp1/4-/- and WT mice infected subcutaneously with 2 x 106 CFU/mouse S. aureus USA300 (SA) 
for 5 days.  
(D) Baseline cytokines from PBS-treated WT and Mlkl-/- mice.  
(E) Cytokines from S. aureus infected WT and Mlkl-/- mice. 
(F) Baseline cytokines from PBS-treated WT and Casp1/4-/- mice.  
(G) Cytokines from S. aureus infected WT and Casp1/4-/- mice. 
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 






Ripk3-/- mice exhibited increased S. aureus clearance during skin infection – To characterize 
further the role of necroptosis in S. aureus host defense, we evaluated the response of Ripk3-/- 
mice to infection (Figure 3.6). RIPK3 is a target of RIPK1 and a major effector of necroptosis 
(94, 95). However, RIPK3 can regulate several other pathways that can influence inflammation, 
including NF-κB, apoptosis and NLRP3 inflammasome pathway (43). In contrast to the Mlkl-/- 
mice or Nec-1s-treated mice, we noted significantly improved outcome in the Ripk3-/- mice 
marked by decreased staphylococcal burden, despite no change in lesion sizes (Figures 3.6A-C). 




Figure 3.6. Ripk3-/- mice exhibit increased S. aureus clearance during skin infection 
(A) S. aureus CFU recovered on day 5 on day of infection on Ripk3-/- and wild type (WT) mice infected 
subcutaneously with S. aureus (SA) for 5 days.  
(B) Representative images of mice showing lesions on day 5 of skin infection. 
(C) Quantification of lesion sizes on day 5.  
(D) Representative images of trichrome stain on skin biopsies of S. aureus-infected mice. Scale bars, 
100 μm. 
Each point represents a mouse and lines show median values. Results shown are pooled from at least 






To understand if the improved phenotype we observed in Ripk3-/- mice was due to their 
ability to regulate inflammation, we analyzed their inflammatory response to S. aureus. We 
observed a diminished inflammatory cell recruitment and a reduced cytokine production 
(including significantly less IL-1 and G-CSF) following infection in Ripk3-/- mice, but no 
differences in baseline cytokine activity between the knockout and WT mice (Figures 3.7A-E).  
 
 
Figure 3.7. Ripk3-/- mice exhibit decreased inflammatory response during S. aureus skin infection 
(A-C) Number of macrophages (Macs) (A) neutrophils (PMNs) (B) and gamma-delta (γδ) T cells (C) in 
infected area.  
(D and E) Cytokines after 5 days of infection with S. aureus (A) or PBS control (B). 
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 







We postulated that the disparity in the results obtained in Ripk3-/- and Mlkl-/- mice were 
likely due to the additional roles of RIPK3, which are independent of its effects on its substrate 
MLKL, such as its ability to activate NLRP3 inflammasome (73), to induce NF-κB (96), to 
activate CaMKII-dependent necrosis (97) and to induce apoptosis in multiple cell types (98-102). 
In the absence of RIPK3, we observed decreased inflammasome activation, as marked by 
decreased production of IL-1β (Figure 3.8A). We also observed less cell death due to apoptosis, 
as shown by decreased Annexin V+ in all cells and immune cells and by decreased TUNEL 
staining in skin biopsies of infected Ripk3-/- mice (Figures 3.8B and 3.8C). Thus, deletion of 
Ripk3 resulted in diminished IL-1 production and decreased apoptosis, resulting in increased 
eradication of infection and reduced inflammation-induced damage.  
 
 





(A) IL-1β produced by Ripk3-/- and WT mice after 5 days of S. aureus skin infection 
(B) Number of total Annexin V+ cells and number of Annexin V+ immune cells (CD54+) after 5 days of 
infection. 
(C) Representative images of trichrome stain (H) or TUNEL (I) on skin biopsies of S. aureus-infected 
mice. Scale bars, 100 μm. 
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 
mean ± SEM. Results shown are pooled from at least two independent experiments. *p<0.05. 
 
Inflammasome is necessary for S. aureus killing – After showing that the lack of Mlkl or 
Casp1/4 contributes to poor outcome, marked by excessive inflammation during S. aureus skin 
infection, we wanted to tease out the exact roles of necroptosis and pyroptosis in bacterial 
clearance. We measured bacterial killing capacity of primary keratinocytes (HEKn), peritoneal 
exudate cells (PECs) and bone marrow-derived macrophages (BMDMs) when necroptosis is 
inhibited. Ripk3-/-, Mlkl-/-, Casp1/4-/- and WT PECs and BMDMs did not have any differences in 
taking up S. aureus (Figures 3.9A and 3.9B). 24 hours after infection, we recovered more S. 
aureus in Casp1/4-/- than in WT PECs and BMDMs (Figures 3.9C and 3.9D). Ripk3-/- and Mlkl-
/- immune cells exhibited no defect in bacterial killing abilities (Figures 3.9C and 3.9D). The 
defect in S. aureus clearance by Casp1/4-/- BMDMs correlated with decreased production of IL-
1β (Figure 3.9E). A similar impairment of S. aureus killing ability was observed in HEKn when 
caspases were inhibited (using ZVAD) but not when necroptosis was blocked (using NSA) 
(Figure 3.9F). These data suggest that the necrosome complex decreases damage during S. 
aureus infection by limiting inflammation, whereas the inflammasome components are essential 






Figure 3.9. Caspase-1/4 but not the necrosome components are necessary for S. aureus killing 
(A and B) S. aureus uptake by mouse peritoneal exudate cells (PECs) (A) and bone marrow-derived 
macrophages (BMDMs) (B) infected with S. aureus for 1 h. 
(C and D) S. aureus killing by PECs (C) and BMDMs (D) infected with S. aureus for 24 h.  
(D) S. aureus uptake by BMDMs from mice after 1 h infection. 
(E) IL-1β released by BMDMs after 4 h stimulation with S. aureus.  
(F) S. aureus killing by primary keratinocytes (HEKn cells) pretreated with 10 µM NSA or 50 µM ZVAD, 
infected with S. aureus for 2 h and treated with gentamicin for 4 h.  
Each point represents a mouse and lines show median values. Data are represented as bar graphs with 
mean ± SEM. Results shown are pooled from at least two independent experiments. *p<0.05, **p<0.01. 
 
Necroptosis contributes to improved outcome in Staphylococcus aureus sepsis 
S. aureus is a major cause of sepsis, associated with higher morbidity and mortality than 
bacteremia caused by other pathogens (92). These infections are increasing in frequency as more 
patients undergo invasive procedures. S. aureus systemic infections are often accompanied by 






Since we observed previously that necroptosis contributed to better outcome by 
regulating excessive inflammation in skin S. aureus infection and not by participating directly in 
bacterial killing, we thought that a systemic model of S. aureus infection would further 
illuminate our understanding of the role of necroptosis in regulating inflammation particularly by 
immune cells. We hypothesized that necroptosis limits inflammation leading to a better outcome 
in S. aureus sepsis. To test this hypothesis, we infected mice retro-orbitally with 1 x 108 
CFU/mouse of S. aureus and treated them with Nec-1s or DMSO. Nec-1s infected mice had 
more bacteria systemically 1 and 2 days after infection compared to DMSO controls (Figure 
3.10A).  
To confirm the results that we obtained with the pharmacological inhibitor of necroptosis, 
we infected Ripk3-/-, Mlkl-/-, Casp1/4-/- and WT mice systemically with S. aureus. Casp1/4-/- mice 
and Mlkl-/- mice died at a faster rate compared to WT mice, even though Casp1/4-/- mice’s 
phenotype was more severe (with median survival of 2 days) compared to Mlkl-/- (with median 
survival of 4 days) (Figure 3.10B). We did not observe any survival differences between Ripk3-/- 
and WT mice (Figure 3.10B). Casp1/4-/- did worse possibly because of the role of caspase-1/4 in 
killing bacteria, whereas Mlkl-/- possibly could not regulate inflammation. Together, these results 







Figure 3.10. Caspase-1/4 and MLKL are essential in S. aureus sepsis 
(A) CFU recovered from blood 1 or 2 days after infection of mice treated with Nec-1s and infected 
systemically with 1 x 108 CFU/mouse of S. aureus via retro-orbital route.  
(H) Kaplan-Meier survival curves of WT (n=19), Ripk3-/- (n=8), Mlkl-/- (n=9) and Casp1/4-/- (n=5) mice after 
retro-orbital injection with 1 x 108 CFU/mouse of S. aureus.  
Each point represents a mouse and lines show median values. Results shown are pooled from at least 




In this chapter, we established that necroptosis regulates inflammation during S. aureus skin 
infection. Inhibition of necroptosis by pharmacological and genetic means led to worse outcome. 
Mlkl-/- or Nec-1s-treated mice had significantly larger lesion sizes and more CFU recovered from 
the infected tissues compared to control groups. A similar outcome was observed in Casp1/4-/- 
mice, which cannot undergo pyroptosis and have limited ability to process IL-1β. The poor 
outcome in Casp1/4-/- and Mlkl-/- mice occurred despite the abundance of immune cells including 
neutrophils, macrophages, and gamma-delta T cells. Unlike Casp1/4-/- immune cells, Mlkl-/- 
PECs and BMDMs had no defect in bacterial clearance showing that necroptosis-driven 
clearance is likely due to its ability to regulate inflammation. 
Unlike Mlkl-/- mice, Ripk3-/- mice had improved outcome with better bacterial clearance 
and decreased inflammation after S. aureus skin infection. We attributed this difference in 
outcome of Ripk3-/- mice versus Mlkl-/- mice to the fact RIPK3 can regulate several inflammatory 
pathways independently of MLKL. Ripk3-/- mice had less production of inflammatory cytokines 
and displayed decreased apoptosis as marked by decreased expression of annexin V on their site 
of infection. These results are in line with previous findings showing that RIPK3 increases 
inflammation (independently of MLKL) by stimulating the NLRP3 inflammasome and IL-1 





(98-102). Thus, unchecked inflammation can exacerbate the injury cause by S. aureus and that 
necroptosis helps limit this damage. 
Adequate amount of inflammation tightly is necessary for bacterial clearance. In the early 
stages of infection, neutrophils have to be recruited briskly to the site of infection to clear the 
pathogens before they disseminate (26). Excessive inflammation, however, can be 
counterproductive – leading to enhanced tissue damage and impaired bacterial clearance (33). 
Thus, as described in the literature and as shown in this chapter, a balance between a quick 
immune response (to clear S. aureus) and excessive inflammation (that may be damaging) is 
essential. Necroptosis works in concert with inflammasome activation, which helps clear 
bacteria, to resolve subcutaneous and systemic S. aureus infection. Targeting the necroptosis 





















Chapter 4: Conclusion 
 
S. aureus is an important human pathogen that causes serious infections marked by cell death, 
inflammation, and tissue necrosis; and associated with significant morbidity and mortality. In 
this work, we defined for the first time the specific roles of RIPK1/RIPK3/MLKL-mediated 
necroptosis during the three common types of S. aureus infection – lung, skin and systemic 
infection. Our findings also added to the current literature on the contribution of apoptosis and 
pyroptosis during S. aureus infection. We showed that apoptosis was not a significant contributor 
to S. aureus-induced cell death. We showed that S. aureus activated pyroptosis, marked by the 
activation of caspase-1 and the release of IL-1β. Inhibition of caspase-1/4 impaired the bacterial 
killing capacity of both immune cells and keratinocytes. Mice lacking Casp1/4 exhibited 
decreased bacterial clearance and increased lesion sizes during S. aureus skin infection and 
increased mortality during sepsis compared to their wild type controls.  
The chief contribution of this work was to the understanding of the specific roles of 
necroptosis during the pathogenesis of S. aureus lung, skin and systemic infection. First, we 
showed through biochemical and genetic means that S. aureus induced necroptosis in multiple 
cell types, including immune and skin cells. Necroptosis in both human and murine cells was 
mediated by S. aureus through its pore-forming toxins. These results were recently confirmed by 
a separate research group, which documented that bacterial pore forming toxins induce 





species (104). Using both pharmacological inhibitors and knockout mice, we then teased out the 
roles of necroptosis in S. aureus pneumonia, skin infection, and sepsis.  
The first section showed that S. aureus targets and kills macrophages through 
necroptosis, eliminating a cell population that is critical for bacterial clearance and inflammation 
resolution in pneumonia. Pharmacological and genetic inhibition of necroptosis led to increased 
bacterial clearance and decreased expression of inflammatory cytokines. This phenotype was 
mediated by pulmonary macrophages in Ripk3-/- mice, which were not only resistant to death, but 
also upregulated anti-inflammatory markers. The improved macrophage survival in Ripk3-/- mice 
corresponded to an improved lung architecture and decreased inflammation. These results need 
to be confirmed using Mlkl-/- mice or kinase-dead knockin Rip3 (KDKI RIP3) mice to ensure that 
the observations that we made were not due to the scaffolding effects of RIPK3, which include 
activation of the inflammasome, induction of apoptosis, and activation of NF-κB (105). 
In the second section, we demonstrated the complex roles of necroptosis in dampening 
inflammatory responses to S. aureus skin and systemic infections. Using a combination of 
knockout mice and biochemical inhibitors, we showed that mice that are unable to activate 
necroptosis have greater tissue damage, greater proinflammatory cytokine production and 
increased immune cell recruitment but significantly higher bacterial loads compared to control 
mice. Unlike Mlkl-/- or necrostatin-1s-treated mice, Ripk3-/- mice cleared S. aureus better and had 
decreased inflammation when compared to WT mice. This seemed inconsistent at first, since 
RIPK3 is a key mediator of necroptosis. However, we showed that the direct effects of RIPK3 in 
modulating inflammation – by directly activating IL-1 and apoptosis – played a more important 







Figure 4.1. Pathways of S. aureus-induced cell death 
S. aureus can activate apoptosis, necroptosis and pyroptosis through its virulence factors. S. aureus 
toxins can induce both necroptosis and pyroptosis. RIPK1/RIPK3/MLKL proteins mediate necroptosis. All 
these pathways are interlinked and they potentially occur concurrently in different infected cells. 
 
 
Mlkl-/- and Casp1/4-/- mice had significantly greater mortality from staphylococcal sepsis 
than wild type and Ripk3-/- mice. Casp1/4-/- mice phenotype could possibly be due to the role of 
caspase-1/4 in mediating clearance of intracellular S. aureus. Inhibition of necroptosis led to 
defective bacterial clearance and increased mortality in a model of S. aureus sepsis, even though 
immune cells that were unable to undergo necroptosis had no bacterial killing defect. This 
phenotype could possibly be explained by the role of necroptosis in regulating inflammation, 
which in turn leads to better bacterial clearance and increased survival. Our observations are 
consistent with recent publications that show the complex role of necroptosis – particularly the 
role of necroptosis in limiting pathological inflammation by eliminating the source of 





The contributions that we made on the roles of necroptosis seem to be inconsistent, with 
necroptosis being detrimental in S. aureus pneumonia, while being beneficial in skin and 
systemic infection. This disparity could potentially be because necroptosis-mediated 
inflammation in pneumonia leads to lung damage. Necroptosis in the skin and in the periphery, 
however, decreases excessive inflammation leading overall improved outcome.  
The observed differences in the role of necroptosis between outcome in skin and lung S. 
aureus infection is similar to the dichotomy observed in the role of inflammasome in different 
tissues. Nlrp3-/-- and Casp1/4-/- mice, as well as mice that cannot produce or respond to IL-1β, 
have less severe pneumonia compared to WT mice (50, 106). On the other hand, Casp1/4-/- and 
Il1b-/- mice have more severe S. aureus skin and systemic infection than WT mice (26, 107). 
These findings provide new insights into the opposing roles of different inflammatory pathway 
during S. aureus infection and suggest paying attention to the site of infection in designing 
immunomodulatory therapy to target these pathways. 
It appears that pyroptosis, apoptosis and necroptosis are intertwined. Our finding that 
Ripk3-/- mice had decreased apoptosis and inflammasome activation during S. aureus skin 
infection adds to the growing body of literature showing the multiple roles of the kinase and 
scaffolding functions of RIPK3 (105). The connection between MLKL and the caspase-1 
remains unresolved however. Inhibitors of MLKL blocked caspase-1 and IL-1β production in 
vitro. However, this finding was in conflict with our observations in vivo, where we showed that 
Mlkl-/- mice exhibited upregulated caspase-1 activity and increased IL-1β release after S. aureus 
skin infection. Therefore, exactly how S. aureus toxins activate the necrosome components and 
how the necrosome complex regulates the inflammasome remain important questions for future 





necessarily redundant. Specifically, caspase-1/4, and not any of the necrosome components 
(RIPK3 and MLKL), is required for killing of intracellular S. aureus killing by host cells.  
These studies have expanded the current understanding on the role of necroptosis during 
S. aureus infection and have proffered some interesting applications. Since necroptosis has tissue 
specific roles, understanding the site of infection is essential for developing and administering 
beneficial necroptosis-modulating drugs. For instance, one could develop specific molecules to 
target and prevent S. aureus-induced necroptosis in pneumonia or compounds to activate 
necroptosis in S. aureus systemic and skin infection. Caution must be taken when developing 
drug targets for necroptosis and cell death pathways in general though. One big concern with 
blocking necroptosis is that it may allow development and propagation of tumorigenic cells. 
Bearing in mind the complex roles of necroptosis, targeting this pathway holds great therapeutic 
potential in S. aureus infection. 
Finally, we have addressed the complex roles of necroptosis during S. aureus lung, skin 
and systemic infection. We showed that whereas necroptosis induced lung damage and 
contributed to poor outcome during S. aureus pneumonia, it dampened inflammation and 
improved outcome during S. aureus skin and systemic infection. Future projects may work on 
fully understanding how S. aureus products activate necroptosis and the role of necroptosis in 
infections using humanized mice. Ultimately, developing “druggable” targets and making 
targeted drugs for this pathway offer promising alternatives or complementary therapy to 
antibiotics and could improve healthcare outcomes and reduce morbidity, mortality and huge 






Chapter 5: Materials and Methods 
 
Bacteria. These are the Staphylococcus aureus strains used in this research: (a) Wild type 
USA300 LAC, α-hemolysin (hla), phaH35L and the complemented phla mutants (obtained from 
Juliane Bubeck-Wardenburg, University of Chicago, IL). (b) Wild type USA300 LAC and 
Panton-Valentine leukocidin (lukS-F/PV pvl; lukSF) mutant (obtained from Frank DeLeo, 
National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratories, MT) and 
complemented mutant (Δpvl/pvl+; provided by Binh Diep, UCSF). (c) α, β and γ phenol-soluble 
modulins (PSMα/β/hld) triple mutant (obtained from Michael Otto, National Institute of Allergy 
and Infectious Diseases, MD). (d) lukAB (obtained from Victor Torres, NYU Langone Medical 
Center, NY) and (e) agr null strain.  
WT S. aureus and mutant strains were grown overnight in Luria Broth (LB) at 37°C to a 
stationary phase. The strains were diluted to 1:100 in broth and grown to OD 1.000. S. aureus 
was spun down at 10,000 x g and suspended in phosphate buffered saline (PBS) to achieve the 
required density. To heat-kill the bacteria, we incubated the cultures at 65°C for 1.5 h. We 
obtained S. aureus supernatant by growing USA300 LAC and mutant strains overnight to 
stationary phase in LB and spinning down the bacteria at 10,000 g for 5 minutes. Supernatant 
from the cells were purified by passing it through a 20-µm pore size sterile filter (Millipore).  
 
Mice. C57BL/6J (Jackson Laboratory), Casp1/4-/- (B6N.129S2-Casp1 tm1Flv/J, Jackson 
Laboratory) (108), Ripk3-/- (Vishva Dixit, Genentech) (109) and Mlkl-/- (John Silke, Walter and 
Eliza Hall Institute of Medical Research via Douglas R. Greene, St. Jude Children’s Research 







Mouse model of pneumonia. Six- to seven-week-old sex-matched wild type and Ripk3-/- mice 
were anesthetized with 100 mg/kg ketamine (Henry Schein) and 5 mg/kg xylazine (Henry 
Schein). Mice were inoculated intranasally with 107 CFU/mouse of WT S. aureus or agr null 
mutant in 50 µl of PBS. 18 to 20 hours after infection, mice were sacrificed, bronchoalveolar 
lavage fluid (BAL) obtained and lungs harvested. Recovered bacteria (CFU) were enumerated by 
serial dilutions on Luria Bertani (LB) agar plates and CHROMagar (Becton Dickinson) S. aureus 
plates and incubating the plates overnight at 37°C as previously described (106, 111).  
Mouse cells were obtained and stained as described below and BAL protein content 
measured by Bradford assay (111). Lungs were fixed in 4% paraformaldehyde overnight and 
maintained in 70% ethanol before paraffin sectioning. Lung histology was done by the Columbia 
University Molecular Pathology Shared Resource (MPSR) core as previously described (36). 
Images were taken on an Olympus Cx41 microscope using a Canon Powershot S5IS camera. 
To inhibit necroptosis by pharmacological means, C57BL/6J mice were treated with 300 
µg RIPK1 Inhibitor II, 7-Cl-O-Nec-1 (Nec-1s, Calbiochem) or DMSO 18 hours before and at the 
time of infection. Treated mice were infected with 107 CFU/mouse S. aureus and sacrificed 4 
hours after infection. We counted bacteria and stained cells as described above.  
 
Mouse model of skin infection. Mice were anesthetized as described above, shaved on the back 
and inoculated subcutaneously with 2 x 106 CFU/mouse of S. aureus in 100 μl of PBS using 
26G5/8 sterile needle (Becton Dickinson &Co.). Lesions sizes (mm2) were monitored daily and 





treated mice with 10mg/kg Nec-1s or DMSO control 24 hours before infection, during infection 
and daily for 4 days post-infection. Mice were sacrificed 5 days after infection and analysis done 
as described below. 
Two three-millimeter punch biopsy (Premier Uni-Punch) skin specimens were obtained 
from the lesions of infected mice. The first biopsy tissue was fixed in 4% paraformaldehyde for 1 
day and stored in 70% ethanol. The Columbia University Medical Center Histology Core 
performed Trichrome and TUNEL staining on the paraffin sections. Images were taken on Zeiss 
Axiocam MRc 5 microscope (Zeiss). 
The second biopsy tissue was homogenized using a cell strainer to obtain a single cell 
suspension in PBS. We enumerated recovered bacteria (colony forming units, CFU) from the 
homogenate by serial dilutions on Luria Bertani (LB) agar plates at 37°C. We spun down host 
cells and used homogenate for ELISA and stained cells for FACS as described below. 
We performed skin grafts on NOD-scid IL2Rγnull (NSG, Jackson Laboratory) (112) mice 
as previously described (8). After successful engraftment, we infected skin grafts for 3 days, 
excised the grafts, and fixed them for histopathological analysis (8). 
 
Mouse model of sepsis. 1 × 108 CFU/mouse of S. aureus in 100 μl PBS was delivered 
intravenously through the retro-orbital injection route to six- to eight-week-old anesthetized 
mice. We monitored survival every day. For pharmacological inhibitor experiments, we treated 
mice with 10mg/kg Nec-1s or v/v DMSO control 24 hours before infection, during infection and 
4 hours (for 24 h experiments) or 24 hours (for 48 hour experiments) post infection. We 
sacrificed mice 24 hours or 48 hours after infection and enumerated bacteria and analyzed 






Lung macrophage depletion. Lung macrophages in mice were depleted by intranasally 
administering 75 μl clodronate-loaded liposomes or PBS-loaded liposomes for control group 
(ClodronateLiposomes.org, Netherlands). Mice were infected with S. aureus and sacrificed 4 and 
24 hours post-infection. Macrophage depletion in lung and BAL of the mice was confirmed by 
flow cytometry analysis. 
 
Flow Cytometry: 
Pneumonia. Bronchoalveolar lavage fluids (BAL) were obtained by instilling 3 × 1 ml of PBS 
into the trachea of euthanized mice. Lungs were harvested and passed through a cell strainer 
(Fisher Scientific) with 400 µl PBS to obtain single cell homogenate. BAL was centrifuged at 
200x g for 10 minutes and lung homogenate at 400x g for 6 minutes. Red blood cells were lysed 
and the remaining cells washed with FACS buffer (10% fetal bovine serum and 0.1% sodium 
azide in PBS). Cells were suspended in 100 µl FACS buffer and stained for 30 minutes at 4°C in 
presence of counting beads (Bang Laboratories, Inc.).  
Murine cells were stained with a combinations of fluorescein isothiocyanate-labelled 
(FITC) anti-Ly-6G (Gr-1; RB6-8C5; Biolegend), peridinin chlorophyll (PerCP)-Cy5.5-labelled 
anti-CD11c (N418; Biolegend), allophycocyanin (APC)-labelled anti-MHC II (I-A/I-E; 
Biolegend), phycoerythrin(PE)-labelled anti-NK 1.1 (NKR-P1C, Ly-55; Biolegend), FITC-
CD200R (Biolegend), PE-CD86 (eBiosciences), FITC-CD54 (Biolegend), PE-CD206 
(Biolegend) and propidium iodide (PI, Life Technologies). Neutrophils (Ly6G+/MHCII−), 
macrophages (CD11C+/MHCIIlow-mid) and dendritic cells (CD11c+/MHCIIhigh) were analyzed 






Skin infection. Homogenized skin cells were suspended in 100 μl FACS buffer and stained for 
30 minutes at 4°C combinations of phycoerythrin (PE) anti-CD54 (YN1/1.7.4, Biolegend), 
fluorescein isothiocyanate-labelled (FITC) anti-Ly-6G (Gr-1; RB6-8C5; Biolegend), peridinin 
chlorophyll (PerCP)-Cy5.5-labelled anti-CD11c (N418; Biolegend), allophycocyanin (APC)-
labelled anti-MHC II (I-A/I-E; Biolegend) and APC-labelled anti-TCR γδ T cells (γδ T cells) 
were used. Neutrophils (PMNs; Ly6G+/MHCII−), macrophages (Macs; CD11C+/MHCIIlow-mid) 
and γδ T cells were analyzed using FlowJo_V10 (FlowJo, LLC). 
 
Cytokine analysis. Cytokine levels from BAL fluid were quantified using human IL-8 (BD 
Pharminogen), TNF (Biolegend), IL-6 (Biolegend) and IL-1β (R&D systems) and mouse 
CXCL1/KC (R&D Systems), TNF (Biolegend), IL-6 (Biolegend) and IL-1β (Biolegend), IL-1α 
(Biolegend) were quantified by ELISA according to manufacturer’s instructions. Cytokine levels 
from THP-1 supernatants were quantified using human IL-1β (R&D Systems) ELISA. 
Multiplex ELISA on skin homogenate was performed by Eve Technologies Corporation 
(Calgary, Canada) and analyzed using Microsoft Excel to determine mouse cytokine levels.  
 
Cell Culture: 
Immune cells.  
THP-1 human monocytic cells (THP-1 cells, ATCC) were grown in RPMI1640 medium 
(CellGro) with 10% heat inactivated fetal bovine serum (FBS, Mediatech) and 1% 





environment. THP-1 cells were activated with 1 µM PMA (Sigma-Aldrich) for 24 hours and 
weaned to RPMI1640 medium with 10% FBS but without antibiotics for 24 hours.  
Human primary macrophages were isolated from 40 ml of heparinized blood from 
consenting, healthy anonymous volunteers. Human macrophages were grown for 7 days in RPMI 
1640 medium supplemented with 10% FBS, penicillin-streptomycin and 60 ng/mL M-CSF 
(PeproTech).  
Alveolar macrophages were isolated from de-identified human bronchoalveolar lavage 
(BAL) fluid that would have otherwise been discarded (Columbia University IRB-AAAI5300). 
BAL was passed through a sterile cell strainer (Fisher Scientific) to remove mucus and treated 
with RBC lysis buffer. Cells were washed in PBS and suspended in 1640 RPMI medium 
supplemented with 10% FBS and maintained at 37°C and 5% CO2 in a humidified environment. 
 
Skin cells. 
HaCaT and HEKn cells were grown to confluence in DMEM medium (Gibco) with 10% FBS 
and 1% penicillin and streptomycin at 37°C and 5% CO2 in a humidified environment. Cells 
were maintained in DMEM with 10% FBS but no antibiotics for 24 hours before infection.  
 
Necroptosis inhibition in vitro. 
THP-1 cells and human primary macrophages were pretreated 1 hour before S. aureus infection 
with 200 μM necrostatin-1 stable (Nec-1s, Enzo Life Technologies), 10 µM necrosulfonamide 
(NSA, Calbiochem), DMSO control (v/v), 10 mM N-acetyl-L-cysteine (NAC, Sigma), 1 mM or 
2.5 mM 100,000 MW dextran (Sigma) or 60 mM KCl (Sigma). THP-1 cells and human primary 





Alveolar macrophages were pretreated with 10 µM necrosulfonamide (NSA) or DMSO (v/v) for 
1 hour. Alveolar macrophages were stimulated with S. aureus MOI of 100 for 2 hours. HaCaT 
and HEKn cells were pretreated 1 hour prior to infection with increasing concentration (0 - 200 
μM) of necrostatin-1 stable (Nec-1s, Enzo Life Technologies), 10 μM necrosulfonamide (NSA, 
Calbiochem), 10 μM GSK’872 (Calbiochem), DMSO control (v/v). HaCaT and HEKn cells were 
stimulated with S. aureus MOI of 10 for 4 hours. Cytotoxicity was measured by lactate 
dehydrogenase (LDH) assay (Roche) as described below. 
 
S. aureus uptake and killing assays. 
Peritoneal exudate cells (PECs). Mice were injected intraperitoneally with 107 CFU of heat-
killed S. aureus 48 h and 24 h prior to peritoneal exudate cells (PECs). PECs were obtained by 
washing peritoneal cavity of the mice with 8 ml of PBS (113). Red blood cells were lysed and 
cells kept in ice. S. aureus MOI of 10 was coated for 30 mins with 50% normal mouse serum 
(NMS, Innovative Research) in RPMI 1640 medium (Gibco), washed in PBS and suspended in 
RPMI 1640 medium. Microtiter plates were coated with 20% NMS in RPMI for 60 min at 37C, 
washed to remove residual serum and the plates chilled in ice. PECs were infected with 
opsonized S. aureus MOI of 1 in coated plates for 1 h and 24 h. PECs were lysed with 0.1% 
saponin and bacteria enumerated by serial dilutions on Luria Bertani (LB) agar plates at 37°C.  
 
Gentamicin protection assays.  HaCaT cells were stimulated for 2 hours and BMDMs for 20 
minutes with S. aureus MOI of 100. Cells were washed and treated with 500 µg/ml of 
gentamicin for 1 h and 24 h. Cells were washed in PBS, lysed with 0.1% saponin and bacteria 






siRNA knockdown. HaCaT and THP-1 cells grown in 24-well plates to confluence. Cells were 
transfected with 100 nM RIPK3, non-targeting siRNA (human ONTARGETplus siRNA pools of 
four oligos; Dharmacon) or MLKL (human MLKL siRNA pools of three targets, Santa Cruz 
Biotechnology) using Lipofectamine RNAiMAX (Life Technologies). After 3 days, cells were 
infected with S. aureus (MOI of 10) or PBS for 2 h (THP-1s) or 4 h (HaCaT). Knockdown was 
confirmed by immunoblotting of cell lysates and level of cytotoxicity determined in the cell 
supernatants as described below. 
 
Cytotoxicity assays. Level of cytotoxicity in cells was measured using LDH kit (Roche) as per 
manufacturer’s instructions or using 2µg/mL propidium iodide (Life Technologies) staining. 
Maximal death was achieved freezing and thawing cells multiple types to release maximal LDH 
or to achieve 100% PI staining. Cell culture medium alone used as a baseline. Fluorescence 
intensity was read on a Tecan Microplate Reader (Tecan Group). LDH assay was used in most 
assays except in the instance where the reagents (for example, NAC) interfered with the LDH 
reagents. Necrotic cells were imaged using a Zeiss Observer.Z1 microscope with AxioVision 
software (version 4.6.2.0; Zeiss). 
 
Immunoblotting. HaCaT and THP-1 cells were lysed using RIPA buffer (20 mM Tris-Cl, 50 
mM NaCl, 0.1% SDS, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 0.5% sodium 
deoxycholate) containing 1X Halt protease and phosphatase inhibitor cocktail (Thermo 
Scientific). Proteins were separated on Bolt 4%–12% Bis-Tris Plus gels (Life Technologies), 





TBST (Tris-buffered saline plus Tween) (50 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween) or 
5% bovine serum albumin (BSA) in TBST for 1 hour at room temperature.  
Secreted S. aureus toxin expression was determined in cultures grown overnight in LB to 
stationary phase and supernatant filtered. pvl and pvl/pvl+ complemented mutant and their WT 
controls were grown to exponential phase in CCY media at 37°C and filter sterilized (114). 
Supernatants were ran on a gel and immunoblotted as described below. 
Immuno-detection was performed using anti-MLKL (phospho S358) (Abcam), anti-
MLKL (Abcam), RIPK3 (Santa Cruz Biotechnology Inc.), anti-caspase-1 (Santa Cruz 
Biotechnology Inc.), anti-Caspase-1 (p20) (Casper-1, Adipogen), β-actin (Sigma-Aldrich), Hla (a 
gift from Juliane Bubeck-Wardenburg) and LukF (IBT Bioservices) antibodies followed by 
secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology Inc.). 
Equal loading was confirmed by staining the gels with 0.1% Ponceau S (w/v) in 5% acetic acid 
(Sigma). Densitometry was determined by ImageJ (NIH). 
 
Immunohistochemistry. 5 mm sections from paraffin blocks were mounted on glass slides. The 
sections were deparaffinalized in xylene alternative (Safe Clear, Protocol) and ethanol. Antigens 
were exposed using Tris-EDTA buffer (10mM Tris Base, 1mM EDTA Solution, 0.05% Tween 
20, pH 9.0) at 70oC overnight. Sections were permeabilized with Tween 20 0.5% for 10 minutes, 
hydrated with 0.3% H2O2 for 10 minutes, and stained with anti-MLKL (phospho S358, Abcam), 
anti-MLKL (Abcam), anti-DAPI (Santa Cruz Biotechnology) and anti-pan cytokeratin (Santa 
Cruz Biotechnology) followed by peroxidase staining using the Immunocruz ABC Staining kit 
(Santa Cruz Biotechnology Inc.). Control sections were stained with secondary antibodies only. 






RNA analysis. RNA was isolated and analyzed as described previously (115). Sequences for 
mouse Tnf, KC, Il6 and actin primers have been published elsewhere (115). Here is a list of 
primers used: 
Human actin: 5’-GTGGGGCGCCCCAGGCACCA-3’; and 5’-
CGGTTGGCCTTGGGGTTCAGGGGGG-3’;  
RIPK3 -- 5’-CTCTCTGCGAAAGGACCAAG-3’ and 5’- CATCGTAGCCCCACTTCCTA-3’;  
MLKL -- 5’-CTCTTTCCCCACCATTTGAA-3’ and 5’-TCATTCTCCAGCATGCTCAC-3’ 
IL15 -- 5’-GAAGTATTTCCATCCAGTGC-3’, 5’-CTTCATTGCTGTTACTTTGC-3’;  
IL6 -- 5’-AAGAGTAACATGTGTGAAAGC-3’, 5’-CTACTCTCAAATCTGTTCTGG-3’;  
CSF2 -- 5’-GAACCTGAGTAGAGACACTGC-3’, 5’-AGGTGATAATCTGGGTTGC-3’;  
ACTB -- 5’-TCCTCCCTGGAGAAGAGCTAC-3’, 5’-TAAAGCCATGCCAATCTCATC-3’;  
TNF -- 5’-GAGTGACAAGCCTGTAGCCCA-3’, 5’-GAATGATAAAGTAGACCTGCC-3’;  
CCL20 -- 5’-GTGCTGTACCAAGAGTTTGC-3’, 5’-CAAGTCTGTTTTGGATTTGC-3’;  
IL8 -- 5’-GTGCAGTTTTGCCAAGGAGT-3’, 5’-CTCTGCACCCAGTTTTCCTT-3’;  
CXCL11 -- 5’-AGTCATAGCCACACTCAAGAATGG-3’, 5’-
GATGCAGGATTGAGGCAAGC-3’;  
CXCL10 -- 5’-TTCCTGCAAGCCAATTTTGT-3’, 5’-TTCTTGATGGCCTTCGATTC-3’;  
IL23 -- 5’-GAGGGAGATGAAGAGACTAC-3’, 5’-TTTAGGGACTCAGGGTTGCT-3’;  
CCL2 -- 5’-GCCTGAGTAACTGTGAAAGC-3’, 5’-GAAAACTGGACATTGTTTGC-3’;  
IL1b -- 5’-ATGATGGCTTATTACAGTGGCAA-3’, 5’-GTCGGAGATTCGTAGCTGGA-3’;  
IL17 -- 5’-GCTGTCGATATTGGGGCTTG-3’, 5’-GGAAACGCGCTGGTTTTCAT-3’;  





IL10 -- 5’-ATGAGCATTCAGACTGGGTAAAC-3’, 5’-TTTTAGGGGCTAAGAAACGCAT-
3’;  
CCL7 -- 5’-AGCTCTCCAGCCTCTGCTTA-3’, 5’-CTGCTTTCAGCCCCCAG-3’;  
IL27 -- 5’-GCTGACTCTGAACTCCCTCC-3’, 5’-AGACGGCAGGCGACCTT-3’;  
CSF1 -- 5’-TGGCGAGCAGGAGTATCAC-3’, 5’-AGGTCTCCATCTGACTGTCAAT-3’ and  
TNFSF10 -- 5’- CTCTCTTCGTCATTGGGGTC-3’ and 5’-TGCAGTCTCTCTGTGTGGCT-3’. 
All RNA expressions were normalized to actin. 
 
Ethics statement. Animal work in this study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health, the Animal Welfare Act and the U.S. federal law. The Institutional Animal 
Care and Use Committee (IACUC) of Columbia University approved the protocol (AC-
AAAG9307, AC-AAAH2350 and AC-AAAG7408). Alveolar macrophages were isolated from 
de-identified human bronchoalveolar lavage fluid (Columbia University IRB-AAAI5300) that 
would have otherwise been discarded. All subjects enrolled provided voluntary informed written 
consent and signed a copy of the appropriate and stamped consent documents. Copies of the 
consent documents were given to the subjects for their record. Human primary macrophages 
were isolated from 40 ml of heparinized blood from consenting, healthy anonymous volunteers 
with informed oral consent (Columbia University IRB-AAAC5450). Columbia University 
Institutional Review Board approved a waiver for documentation of consent for blood collection 






Statistical Analysis. Samples with normal distribution were analyzed by two-tailed 
Student's t test. Data with multiple comparisons were analyzed using one-way ANOVA followed 
by Bonferroni corrections to correct for multiple comparisons. Mouse cytokines, bacterial 
counts, and immune cell numbers and other samples with non-normal distributions were 
analyzed using the nonparametric Mann-Whitney test. Outliers were determined by Grubb’s test 
(GraphPad Software, Inc.) and removed. Differences in groups were considered significant if p < 
0.05. Statistical analyses were performed using GraphPad Prism Version 4.00 (GraphPad 
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